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ABSTRACT
Glioblastoma multiforme (GBM), or simply glioblastoma, is the most common
and aggressive primary brain tumor, with a prevalence of approximately 20,000 new
cases per year in the United States and a 3-year survival rate of just 2%. Quercetin
(QCT) is a dietary flavonoid that can be found in common foods such as red kidney
beans, cilantro, and onions. Despite little evidence showing any benefits through dietary
intake of QCT, various studies show its promising anti-cancer results in vitro. In
glioblastoma, QCT is able to cause significant amounts of apoptosis through a variety of
mechanisms. These include activation of caspase-9 and caspase-3, deactivation of matrix
metalloprotease-2 (MMP-2), inhibition of heat-shock protein-27 (HSP-27) and HSP-72,
and increased p53 activity. Autophagy is a natural occurring survival mechanism that is
induced when cells are subjected to environmental stressors like nutrient deprivation,
high heat, or hypoxia. As a result, many synergistic studies are being performed with
QCT in order to find out adequate autophagy down regulation that could complement
QCT for enhancing its apoptosis inducing capabilities. Synergism is the concept of two
substances providing a greater affect than the sum of their individual affects. Drugs
acting in synergism with each other is a promising investigative avenue for many
alternative cancer treatments, including GBM.
The drugs QCT and Sodium Butyrate (NaB) were investigated under autophagic
conditions in three GBM cell lines in order to test their efficacy in slowing the

iv

growth of glioblastoma cells in-vitro due to the reduction of autophagy. The three
glioblastoma cell lines tested are C6 (rat), T98G (human), and LN18 (human). The
results of this study showed a marked increase in apoptosis in all three GBM cell lines,
with the most occurring in T98G. Apoptosis levels were determined via Wright Staining
and Annexin V/PI staining. QCT + NaB combination treatments were also found to
reduce serum-starved induced autophagy in all cell lines with the most prominent
occurring in T98G. QCT alone was also found to be an autophagy inhibitor at a 25 µM
concentration. These results were confirmed via acridine orange staining and western
blotting. QCT + NaB was also found to act in synergism to reduce poly (ADP-ribose)
polymerase-1 (PARP-1), a DNA repair enzyme, and survivin, an anti-apoptotic protein,
expression in C6 cells, which further confirmed the potential efficacy of QCT + NaB to
be used in conjunction with conventional chemotherapeutic therapies.
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CHAPTER 1

INTRODUCTION
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Glioblastoma multiforme (GBM), also known as simply glioblastoma, is the
deadliest and most aggressive malignant primary brain tumor. Typically existing as an
astrocytoma, glioblastoma tumors most commonly reside in the cerebral hemispheres;
however, they can emerge anywhere throughout the central nervous system.

Although it

accounts for only 14.9% of all primary brain cancers, it has the highest prevalence of
malignancy out of any brain tumor. These tumors become more frequent with age and
more commonly affect men than women. Patients diagnosed with GBM have a median
survival of 14.6 months with the current standard treatments. According to the American
Brain Tumor Association, children with high grade tumors have a better prognosis than
adults; with a 5 year survival rate of 25%, whereas adults have a 5 year survival rate of
10%.
The most prevalent symptoms include seizures, nausea, headaches, and vomiting.
Upon diagnosis, first line therapies include surgical resection in conjunction with
simultaneous radiotherapy and chemotherapy. In most cases, complete surgical resection
is difficult due to the undefined borders of GBM tumors. They often spread throughout
the cerebral hemispheres with tentacle-like extensions, which makes total resection
without the loss of essential brain functioning nearly unattainable. Standard
chemotherapy utilizes Temozolomide (TMZ), which is a DNA methylating/alkylating
agent that targets O6 guanine residues, resulting in a cessation of growth in the G-2 phase
(Sang et al., 2014). Radiation therapy has been shown to increase overall median
survival times and improve quality of life (Messaoudi et al., 2015).
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Figure 1.1: MRI image showing tentacle-like extensions of a GBM tumor located in the
right hemisphere (Courtesy of Medscape).

After approximately 12 months of TMZ treatment, most GBM tumors become
resistant to the tumor DNA alkylation. This occurs due to the increased activity of O 6methylguanine DNA methyltransferase (MGMT) repair enzyme in GBM tumors, which
leads to chemoresistant phenotypes. This mechanism, along with rapid growth and
undefined borders, are the core cause of the low survival rates of GBM patients. Because
of this, alternative therapies are being widely researched. The only FDA approved
second-line GBM treatment is Bevacizumab, which is an antibody targeting vascular
epithelial growth factor (VEGF). VEGF is highly upregulated in GBM and is responsible
for glioblastoma endothelial cell proliferation (Hottinger et al., 2014). Other second-line
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therapies include Cediranib, Vatalanib, Aflibercept, and Cilengitide; however, they have
shown little-to-no efficacy in clinical trials.
The aim of the current study is to explore the therapeutic potential of a secondline therapy using QCT and NaB synergistically with each other. QCT is a natural
bioflavonoid that is most widely known for its anti-inflammatory properties. But in
recent years, QCT has proven to contain anti-cancer properties in a variety of tumors,
including glioblastoma. QCT has been shown to induce apoptosis in GBM through
multiple mechanisms that include activation of caspase-9 & caspase-3 and
downregulation of heat shock proteins (HSP) 72 & 27 (Taylor and Ray, 2017). But
despite its anti-cancer potential, QCT is not without its downsides. QCT has also been
shown to alter autophagy in various GBM cell types. It was demonstrated in U373MG
cells that QCT upregulated autophagy (Kim et al., 2013), whereas QCT was able to block
autophagy in U87 and U251 when paired with the drug t-AUCB (Li et al., 2016).
Autophagy is considered a cell survival mechanism during cancer progression. By
pairing QCT with another drug, it is hypothesized that autophagy will be downregulated
and apoptosis will be synergistically potentiated.
Sodium butyrate (NaB) is a well-known histone deacetylase inhibitor (HDACi)
that is widely used in cancer treatment studies. Histone acetylation is important for gene
expression due to acetylated lysine residues allowing a DNA strand to reside in the
relaxed position. This allows for cell transcription machinery to access genes and
transcribe the corresponding mRNA. The role of a histone deacetylase (HDAC) is to
remove the acetyl groups from lysine residues; thus, returning the DNA into its tightly
coiled form around a histone. Many cancers, including prostate, breast, and lung, have
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HDAC overexpression. This results in repression of essential tumor suppressor and DNA
repair genes (West and Johnstone, 2014). Over the past decade, many clinical trials have
been underway to test the efficacy of HDACi in combination with standard chemo- and
radiotherapies. Valproic Acid in combination with radiation therapy has been shown to
be a radiosensitizer, and Vorinostat (SAHA) in combination with several chemotherapies
has shown synergistic cell death (Lee et al. 2017). But despite NaB being a wellestablished HDACi, few studies have been performed investigating its impact on GBM.
Because of its relatively unknown mechanism and the success of other HDACi drugs in
combination therapy, it was determined that NaB would be the most ideal candidate for
this study.
Autophagy is a cellular response triggered by environmental stressors such as
high heat or nutrient starvation. In recent years, autophagy has become an area of interest
in cancer research due to it serving two opposite roles in the cancer cell cycle. During
tumor development autophagy is a tumor suppressive mechanism; however, during tumor
progression autophagy is a pro-survival mechanism (Yang and Klionsky, 2010). This
enigma opens a door to a new avenue of cancer therapy by downregulating autophagy
during cancer treatment. The effect QCT has on autophagy in glioblastoma remains
controversial. It has been shown to both upregulate and downregulate autophagy in
different GBM cell types. The impact of NaB on autophagy has been largely
undetermined. In order to develop viable cancer therapies, autophagy and its role in
various types of cancer must be better understood. By investigating the synergism of
QCT + NaB on GBM cells under autophagic conditions, the roles of each of these drugs
and their impact on autophagy may be better understood.

5

CHAPTER 2

PROSPECTS OF ENHANCING ANTI-CANCER ACTIVITIES OF
QUERCETIN IN THE TREATMENT OF GLIOBLASTOMA

_____________________
Taylor, M. A., & Ray, S. K. (2017). Prospects of Enhancing Anti-Cancer Activities of
Quercetin in the Treatment of Glioblastoma. Horizons in Cancer Research, 66, 173-192.
Reprinted here with permission of Nova Science Publishers.
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ABSTRACT
Quercetin (QCT) is a dietary flavonoid that can be found in common foods such
as red kidney beans, cilantro, and onions. It is most commonly known as a
neuroprotective agent; but at doses between 12.5 - 100 µM, QCT has been proven to
possess potent anti-cancer activities. Despite little evidence showing any benefits
through dietary intake of QCT, various studies show its promising anti-cancer results
in vitro. The most common and deadly brain cancer is glioblastoma that remains
incurable with any standard chemotherapy. In glioblastoma, QCT is able to cause
significant amounts of apoptosis through a variety of mechanisms. These include
activation of caspase-9 and caspase-3, deactivation of matrix metalloprotease-2 (MMP2), inhibition of heat-shock protein-27 (HSP-27) and HSP-72, and increased p53
activity. In addition to induction of apoptosis, QCT upregulates autophagy in most
glioblastoma cell lines. Autophagy is a naturally occurring survival mechanism that is
induced when cells are subjected to environmental stressors like nutrient deprivation,
high heat, or hypoxia. As a result, many synergistic studies are being performed with
QCT in order to find out adequate autophagy down regulation that could complement
QCT for enhancing its apoptosis inducing capabilities. The most significant hurdle to
overcome with QCT treatment in glioblastoma is developing an efficient delivery
method into the brain to allow its prolonged accumulation in the affected brain tissue.
QCT is rapidly degraded when injected in vivo, which explains why dietary intake is
unable to produce significant results. However, recent studies have shown that QCT is
able to be delivered to the brain, liver, kidneys, and lungs in both mice and pig models
through the use of nanoparticles. Even though much still remains undiscovered, recent
advances made in blood-brain-barrier delivery systems and drug synergism have
7

opened a window of opportunity into future use of QCT as a viable alternative or
addition to standard treatment for glioblastoma.

2.1 - INTRODUCTION
Glioblastoma multiforme, which is also simply called glioblastoma, is one of the
most common and aggressive primary brain tumors. According to the American Brain
Tumor Association, glioblastoma accounts for about 15% of all primary brain tumors
with a median survival of 14.6 months from the time of diagnosis in spite of current use
of surgery, radiotherapy, and chemotherapy. Standard treatment for glioblastoma includes
first surgical resection followed by adjuvant chemotherapy with temozolomide (TMZ)
and radiotherapy. The molecular mechanism of action of TMZ shows that it acts by
methylating the O6 position of guanine nucleotides in genomic DNA, resulting in cell
cycle arrest and cell death (Sang et al., 2014). Recent Phase III clinical trials have shown
that TMZ treatment in conjunction with radiotherapy increased median survival time
from 12.1 to 14.6 months in glioblastoma patients (Hottinger et al., 2014). In most cases,
the brain tumors become resistant to TMZ treatment within a year due to development of
intracellular protective mechanisms such as altered DNA repair enzyme activity, p53
mutations, and overexpression of epidermal growth factor receptor (EGFR) (Haar et al.,
2012; Messaoudi et al., 2015). The negligible success with the current adjuvant therapies
has impelled the necessity for development of alternative treatments in order to improve
the outcomes in glioblastoma patients.
Studies in our laboratory have shown that various flavonoids possess remarkable
anti-cancer properties in the treatment of human glioblastoma in vitro (Das et al., 2010;
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Chakrabarti and Ray, 2015a; Chakrabarti and Ray, 2015b) and also in vivo (Chakrabarti
and Ray, 2016). Quercetin (QCT) is an abundant dietary flavonoid commonly found in
foods such as red kidney beans, chili pepper, cranberry, onion, and tomatoes (Konar,
2013; Dajas et al., 2015). QCT has a basic flavonoid structure consisting of two separate
phenolic rings A and B joined by a 3-carbon heterocyclic ring C and with all the
substitutions in its rings, it is chemically called 3,3,’4,’5,7-pentahydroxyflavone (Figure
2.1). In nature, many flavonoids including QCT are bound to sugars and thus occur in Oglycoside forms due to glycosylation at any hydroxyl group of the flavonoids. The
glycosylated structures of a flavonoid are the most common in nature, not the aglycone or
parent molecule. The most common QCT glycoside has a sugar group at the 3-hydroxyl
position, such as QCT-3-O-glucoside. QCT is highly regarded as a potent anti-oxidant
that acts through its ortho-dihydroxy substitutions in its ring B and also the 2,3unsaturation and 4-carbonyl in its ring C (Dajas et al., 2015). However, recent studies
have clearly shown that QCT possesses significant anti-cancer properties. QCT acts
through multiple molecular mechanisms to induce apoptosis in many types of cancers. In
glioblastoma, QCT triggers the intrinsic apoptotic pathway that includes activation of
caspase-9 and caspase-3 (Badziul et al., 2014), inactivation of heat-shock proteins (HSPs)
(Sang et al., 2014), suppression of PI3K/Akt survival signaling (Pan et al., 2014), and
inhibition of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated
kinase (ERK) kinase (MEK) 1 and Raf1 kinase activities (Lee et al., 2008). This multidirectional approach to induction of apoptosis gives a great potential to QCT to act as an
alternative treatment for glioblastoma.
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Despite the widely proven pro-apoptotic capabilities of QCT in cell culture
studies, many obstacles still have to be overcome before it can be used as a viable
alternative therapy for glioblastoma. The greatest challenge facing QCT therapy is its
instability due to metabolic degradation in vivo. High molecular mass and low water
solubility have hindered the ability of this naturally occurring dietary QCT to accumulate
in the target tissues at therapeutically significant concentrations (Blasina et al., 2015). As
a result, current research efforts have been focused on developing nanosomes that can be
used to prevent metabolic degradation of QCT, allow penetration through the bloodbrain-barrier (BBB), and maintain QCT tissue concentrations at a therapeutically
effective level (Priprem et al., 2008).
Another obstacle with QCT therapy is the current understanding of autophagy and
modulation of induction of autophagy by QCT. Autophagy is a cellular response to
nutrient starvation and other metabolic stressors that prompt recycling of existing
cytoplasmic components in order to be used as an alternative energy source (Cui et al.,
2015). Present studies describe autophagy as either a pro-survival or pro-death
mechanism; therefore, exact role of autophagy in cancer has been difficult to determine
(Moon et al., 2015). QCT is a known up-regulator of autophagy in glioblastoma (Kim et
al., 2013, Cui et al., 2015, Moon et al., 2015). The current understanding of autophagy in
glioblastoma is that it acts as a pro-survival mechanism during glioblastoma progression
(Kim et al., 2013). This emphasizes the need to further investigate capability of QCT to
act synergistically or at least additively when combined with one of the drugs known for
down regulation of autophagy.
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The anti-cancer capabilities of QCT both in vitro and in vivo have been clearly
demonstrated over the past decade. The high prevalence, poor prognosis, and ineffective
therapies for glioblastoma have made the development of alternative therapies a
significant priority. Despite the current obstacles associated with QCT, its profound
therapeutic potential makes it an alternative agent that cannot be ignored. This chapter
will provide a comprehensive overview of the past findings, current research, and future
development paths that can be taken into consideration to use QCT as a viable alternative
therapy for glioblastoma.

Figure 2.1: Chemical structure of QCT molecule. Its molecular formula is C 15H10O7 with
a molecular mass of 302.236 and its IUPAC (International Union of Pure and Applied
Chemistry) name is 2-(3,4-dihydroxyphenyl)-3,5,7-trihydoxy-4H-chromen-4-one.
Chemically, it is also called 3,3,’4,’5,7-pentahydroxyflavone. This chemical structure of
QCT has been established by various organic syntheses.
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2.2 - OVERVIEW OF CURRENT TREATMENTS FOR
GLIOBLASTOMA
Glioblastoma is a malignant, highly aggressive primary brain tumor that almost
always carries a poor prognosis. The incidence of glioblastoma is 3 to 4 in 100,000
people per year (Hottinger et al., 2014). However, the incidence increases with age and is
more common in men. According to the American Brain Tumor Association, about 3%
of the childhood brain tumors diagnosed are considered as glioblastoma. Without
treatment, average survival time is usually less than 1 year. With treatment median
survival ranges around 14 months. Despite a poor prognosis, many patients choose to
undergo surgery and standard treatment with the hopes of extending their survival as
much as possible.
Upon diagnosis of glioblastoma, the first priority is the surgical resection of the
tumor. Glioblastoma typically reside in the cerebral hemispheres, but tumors also have
some potential to appear anywhere throughout the central nervous system. Due to the
highly aggressive nature of glioblastoma, complete surgical resection is often
unattainable. Without complete surgical resection, adjuvant chemotherapy or
radiotherapy is a necessary next step (Hottinger et al., 2014). After surgical resection of
the tumor, radiotherapy combined with simultaneous oral TMZ chemotherapy is the
currently used treatment strategy. TMZ is a DNA alkylating agent that is currently the
standard chemotherapy for treatment of glioblastoma. TMZ induces apoptosis by
methylating O6 guanine residues in genomic DNA in cancer cells, which ultimately leads
to cell cycle arrest at the G2 phase (Jakubowicz-Gil et al., 2013). Standard treatments for
glioblastoma patient involve a daily oral TMZ dose of 75 mg/m 2 of body surface area
(BSA) with simultaneous radiation treatment for the first six weeks (Messaoudi et al.,
12

2015). This is followed by a TMZ dose of 150 - 200 mg/m2 BSA for five consecutive
days every 28 days. Usually within one year, glioblastoma becomes resistant to TMZ and
ultimately cause recurrence of the tumor. TMZ resistance is mainly attributed to many
glioblastoma cells containing O6-methylguanine DNA methyltransferase, which
counteracts the primary cell death mechanism of TMZ. Other resistance mechanisms
include an overexpression of EGFR and p53 gene mutations (Messaoudi et al., 2015).
Due to highly aggressive nature of glioblastoma and poor outcomes of standard
treatment regimen, many alternative targeted therapies are being developed. Currently the
most prevalent second-line glioblastoma treatment is Bevacizumab (Bev), which is a US
Food and Drug Administration (FDA) approved monoclonal antibody that targets
vascular epithelial growth factor (VEGF) (Wang et al., 2016). VEGF and its variants are
highly expressed in glioblastoma cells and other brain tumors (Kloepper et al., 2016).
However, after multiple Phase II and Phase III clinical trials, Bev has been unable to
show a consistent favorable outcome in glioblastoma patients when compared with the
standard regimen of TMZ and radiotherapy (Hottinger et al., 2014). Other alternative
drugs that target factors such as EGFR, BCR-Abl, PI3K/Akt, and mTOR are currently in
clinical trials, but so far these drugs have shown little to no efficacy in treating
glioblastoma patients.
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Figure 2.2: Processes and pathways for synthesis of QCT aglycone from various QCT
glycosides and its biodistribution in animals. Various QCT glycosides are catabolized to
QCT aglycone in small and large intestines. Absorption of QCT aglycone may ultimately
transport it to some extent to the brain.

2.3 - QCT AGLYCONE SYNTHESIS AND BIOAVAILABILITY
QCT is one of the most common dietary flavonoids and it is found in many fruits
and vegetables. In Western countries, it is estimated that an average person has an
average dietary intake of 16 - 25 mg of QCT per day (Dajas et al., 2015). In vivo, QCT
aglycone synthesis and its bioavailability are shown (Figure 2.2). Most of the QCT found
in the diet is in its glycosylated forms, which include isoquercetin (QCT-3-O-glucoside),
spiraeoside (QCT-4’-O-glucoside), rutin (QCT-3-O-rutinoside), hyperoside (QCT-3-Ogalactoside), and quercitrin (QCT-3-O-rhamnoside). Once ingested, QCT glycosides are
hydrolyzed by lactase phlorizin hydrolase in the small intestine and then absorbed via the
sodium-dependent glucose transporter-1 (SGLT-1). After SGLT-1 mediated import,
intestinal processing results in QCT glycosides for their conversion to QCT aglycone,
which is considered to be the most potent anti-oxidant (Murota and Terao, 2003). QCT
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aglycone is quickly processed through secondary metabolism by the liver and then
distributed throughout the bloodstream (Kashino et al., 2015). QCT metabolites then
attach to serum albumin in order to be circulated throughout the blood plasma. These
metabolites have a half-life of 11 to 28 hours, which allow for aggressive
supplementation to increase QCT plasma concentrations to high nanomolar to low
micromolar range (Dajas et al., 2015). Normal dietary plasma QCT levels are typically in
the low nanomolar range.
In order for QCT to be a viable treatment for glioblastoma, it must be able to pass
through the BBB. A recent study performed in rats investigated the ability of dietary
QCT to accumulate in the brain after heavy supplementation by either direct QCT
injection or dietary intake (Ishisaka et al., 2011). The aim of this investigation was to
analyze the neuroprotective effects of QCT and found that QCT was detectable in the rat
brain tissue at the pmol/g level (Ishisaka et al., 2011). An earlier study determined that
rats subjected to an 11-week 1% QCT diet accumulated 330 and 680 pmol/g of brain
tissue (de Boer et al., 2005).
Despite the ability of QCT to penetrate the BBB and accumulate in brain tissue, no
studies have shown dietary or intravenous administration of QCT aglycone or its
metabolites to be a viable method for saturating brain tissue to cancer therapeutic levels.
Some recent in vitro studies, however, have determined that 25 - 100 µM QCT can be an
effective pro-apoptotic concentration in various glioblastoma cell lines (Kim et al., 2013;
Pan et al., 2014). Therefore, it can be implied that QCT dietary supplementation is not an
effective method for achieving sufficient level of QCT in vivo for treating or preventing
glioblastoma.
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2.4 - MECHANISMS OF ACTION OF QCT FOR INDUCING
APOPTOSIS
Over the last decade, QCT has been shown to be a potent anti-cancer compound.
In addition to its free radical scavenging properties, QCT can also induce apoptosis in
glioblastoma cells while showing negligible side effects on normal tissues (Pozsgai et al.,
2013). This unique property has demonstrated that QCT has the potential to be a viable
second-line therapy for inducing apoptosis in human glioblastoma cells (Pan et al., 2014).
Although the complete mechanism of QCT for induction of apoptosis in glioblastoma has
yet to be fully discovered, QCT has been proven to act through an intrinsic multimechanistic pathway leading to final phase of apoptosis. The mechanisms for ultimate
induction of apoptotic cell death due to QCT include down regulation of PI3K/Akt
survival signaling (Pan et al., 2014), inactivation of HSP-27 and HSP-72 (Sang et al.,
2014), inhibition of MAPK pathways (Lee et al., 2008), and also suppression of the
JAK/STAT3 signaling pathway (Michaud-Levesque et al., 2012), and activation of
caspase-9 and caspase-3 (Badziul et al., 2014) in glioblastoma cells (Figure 2.3). This
type of multi-targeted mechanisms of QCT in glioblastoma may hold the key to
combating the chemoresistance issue associated with TMZ treatment and also key to
providing hope of improving patient outcomes.
The most prevalent mechanism of QCT for induction of apoptosis in glioblastoma
is the activation of caspase-9 and caspase-3, as mentioned above. In a recent study, it has
been shown that QCT in a dose dependent manner can increase activation of caspase-9
and caspase-3 (Kim et al., 2013). Maximum activation of caspase-9 occurred at 100 µM
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QCT, while maximum activation of caspase-3 happened at 75 µM QCT in human
glioblastoma U373MG cells (Kim et al., 2013). Caspases play a crucial role in induction
of apoptosis by their contributions to apoptotic pathways that are manifested in
morphological and biochemical features. Caspase-9 is considered an initiator caspase in
the intrinsic mitochondrial pathway of apoptosis (McIlwain et al., 2013). After QCT acts
through the intrinsic mitochondrial pathway, cytochrome c is released from mitochondria
into the cytosol and then cytosolic cytochrome c is combined with Apaf-1 to form an
apoptosome, which recruits pro-caspase-9 and ultimately leads to activation of caspase-9
(Badziul et al., 2014). QCT activates caspase-9 that then proceeds to activate caspase-3
by causing a conformational change to expose active sites on caspase-3 (McIlwain et al.,
2013). Caspase-3 then proceeds to activate various pro-apoptotic proteins including a
DNase that ultimately degrades genomic DNA causing cell death. Activation of caspase9 and caspase-3 by QCT has been widely demonstrated both in single drug (Kim et al.,
2013) and multi-drug combination (Jakubowicz-Gil et al., 2013; Badziul et al., 2014)
studies.
Many other studies have also shown that QCT acts in glioblastoma cells through
the inhibition of the PI3K/Akt survival pathway (Pozsgai et al., 2013). Since its
discovery, the PI3K/Akt pathway has been of great interest due to its crucial role in cell
survival in cancers. Many cancer types have the upregulated PI3K/Akt signaling, which
may be a major contributing factor to chemoresistance (Vara et al., 2004). A recent study
investigating QCT treatments alone or in combination with TMZ in two glioblastoma cell
lines U-251 and DBTRG-05 demonstrated the ability of QCT to down regulate the
PI3K/Akt survival signaling pathway (Pozsgai et al., 2013). QCT significantly decreased
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phospho-Akt levels in glioblastoma cells both in single and TMZ combination treatments.
In a more recent study, it has been demonstrated that PI3K/Akt pathway contributes to
mitochondrial health by promoting anti-apoptotic Bcl-2 stabilization (Pan et al., 2014).
Bcl-2 is an important oncoprotein and well-known for its role in preventing
mitochondrial pathway of apoptosis in cancer cells. Down regulation of the pro-survival
PI3K/Akt signaling pathway enables QCT to induce mitochondrial pathway of apoptosis
in glioblastoma cells. Interestingly, QCT has also been shown to drastically increase
phospho-ERK levels (Pozsgai et al., 2013), which may result in increased Bcl-2
translation. In contrast, a more recent study demonstrated that QCT in a dose dependent
manner decreased phospho-ERK1 levels (Pan et al., 2015). The reason for this
discrepancy has yet to be determined. Obviously, a decrease in phospho-ERK1 is highly
desirable for decreasing the Bcl-2 translation.

Figure 2.3: Molecular mechanisms of action of QCT for inhibition of growth and
induction of apoptosis in glioblastoma cells. Various studies have confirmed the
capability of QCT in down regulating cell migration, PI3K/Akt survival signaling, cell
cycle progression, anti-apoptotic Bcl-2 protein, and HSPs. QCT promotes pro-apoptotic
Bax homodimerization and inhibition of HSPs (HSP-27 and HSP-72) to trigger
mitochondrial release of cytochrome c and facilitate formation of apoptosome,
respectively, leading to activation of the intrinsic pathway of apoptosis in glioblastoma
cells.
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Another mechanism involved in the multi-targeted approach of QCT for induction
of apoptosis in glioblastoma cells is the inactivation of the HSP-27 and HSP-72. These
HSPs play very important roles in cell survival when exposed to stressful environments.
In cancers, HSPs can hinder treatment by inhibiting the intrinsic mitochondrial pathway
of apoptosis. HSP-27 inhibits apoptosis by binding to cytosolic cytochrome c; thus,
stopping it from binding to Apaf-1 to form the apoptosome (Takayama et al., 2003).
HSP-72 functions by acting on Apaf-1 and preventing Apaf-1 from binding to cytosolic
cytochrome c (Badziul et al., 2014) and HSP-72 can also migrate to the nucleus to
prevent nuclear DNA degradation due to caspase-3 mediated activation of a DNase
(Jakubowicz-Gil et al., 2013). Indeed, QCT is considered to be one of the best HSP
inhibitors and it is known to down regulate both HSP-27 and HSP-72 in glioblastoma
cells (Badziul et al., 2014). The ability of QCT to inhibit HSP activity enhances its ability
to induce apoptosis in glioblastoma cells through the intrinsic pathway by further down
regulating anti-apoptotic factors. Due to the oncogenic nature of HSP expression in
cancer cells, inhibition of their activity by QCT demonstrates a novel approach to future
cancer therapies.
QCT also has the ability to inhibit the STAT3 signaling pathway in glioblastoma.
The STAT3 pathway is one of the most studied signal transduction pathways due to its
prevalent and potent roles in inflammation and cancer. It has been demonstrated that
there is a significant correlation between STAT3 activation and tumor malignancy
(Birner et al., 2010). QCT reduced glioblastoma cell growth due to inhibition of the
STAT3 signaling pathway by blocking the phosphorylation of GP130 and simultaneously
suppressing the JAK1 activation (Michaud-Levesque et al., 2012). In glioblastoma, the
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STAT3 pathway is responsible for Bcl-2 upregulation, promoting cell migration through
MMP-2 activation and cell cycle progression through cyclin D1 expression. Results
showed that QCT in a dose dependent manner inhibited MMP-2 secretion in presence of
IL-6. This suggests that QCT is a suitable therapy for preventing glioblastoma invasion
and metastasis. It was also observed that QCT stopped cell cycle progression by
inhibiting cyclin D1 expression. However, inhibition of cyclin D1 expression occurred
only in presence of IL-6 (Michaud-Levesque et al., 2012). It has been demonstrated that
glioblastoma cells heavily secrete IL-6 (Hong et al., 2007) and this provides an
opportunity to QCT to enable its inhibitory effect on cyclin D1 expression for blocking
glioblastoma cell growth.

2.5 - AUTOPHAGY ENIGMA IN QCT THERAPY FOR
GLIOBLASTOMA
Autophagy is a cellular response to environmental stressors such as nutrient
starvation, high heat, or metabolic stress. This process involves intracellular degradation
of cytoplasmic components via acidic lysosomes in order to provide additional amino
acids and other building blocks for essential cellular processes (Cui et al., 2015). In
cancers, autophagy is an important topic because of its ability to either act as a protective
mechanism or promoter of apoptosis. During cancer development, autophagy is
considered to be tumor suppressive mechanism; while during cancer progression,
autophagy promotes cancer cell survival (Yang and Klionsky, 2010). Most cancers are
detected during their progression. It is becoming clear nowadays that novel strategies
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need to be developed to make QCT get around autophagy and put forward apoptosis for
slowing the progression of glioblastoma cell growth (Kim et al., 2013).
Despite the impression that autophagy pathway progresses in a simplistic manner,
its physiological effects remain largely misunderstood. In vitro studies show that
autophagy is most easily triggered through nutrient starvation of the cells in culture. An
autophagic cell then encompasses its organelles into a specialized vesicle, termed the
autophagosome. The autophagosome fuses with acidic lysosome, thereby the engulfed
components are digested and the resulting amino acids and other building blocks are
reused for essential cellular processes (Yang and Klionsky, 2010). Detection of
autophagy is performed by measuring the amount of increase in LC3B II (which is
present in the autophagosome) or the amount of decrease in sequestosome 1 (SQSTM1),
also known as the ubiquitin binding protein p62 (which is a substrate for lysosomal
degradation in the autophagosome), in the cell (Moon et al., 2015).
Autophagy is enigmatic in the use of many alternative and also standard
chemotherapeutic agents for glioblastoma. Several studies have so far demonstrated that
QCT is an up-regulator of autophagy in glioblastoma as well as in other forms of cancer
cells (Kim et al., 2013; Cui et al., 2015; Moon et al., 2015). This property is one of the
major pitfalls of QCT in the treatment of cancer, revealing autophagy being a cellular
protection mechanism during cancer progression. A well-designed study demonstrated
how QCT could induce protective autophagy in human glioblastoma U373MG cell line
(Kim et al., 2013). The same study also showed that QCT was unable to induce
autophagy in human glioblastoma T98G cell line. This is an example of the unique
properties of each human glioblastoma cell line to a specific drug treatment, emphasizing
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the need to develop therapeutic strategies that are effective in many glioblastoma cell
types. Presence of protective autophagy was shown in U373MG cells by measuring the
amount of decease in apoptosis in the cells following treatments with QCT alone and
QCT combined with chloroquine (an anti-malarial drug known to block autophagy). The
results showed that when combined with chloroquine, QCT was capable of inducing
autophagy by utilizing new mechanisms. In addition to activation of caspase-9 and
caspase-3, caspase-7 was also activated in apoptotic cells (Kim et al., 2013). It can be
stipulated that QCT has unforeseen mechanistic approaches to induction of apoptosis that
may be inhibited by autophagy. In order for QCT to be a viable therapy for glioblastoma,
it must be paired with another complimentary drug for acting synergistically or additively
for promoting induction of both extrinsic and intrinsic pathways of apoptosis in various
glioblastoma cell types.

2.6 - QCT SYNERGISM FOR CONTROLLING GLIOBLASTOMA
Synergism, by definition, is the combination of two or more therapeutic agents
that accentuate a greater therapeutic effect, greater than the sum of their individual
effects. This is an important topic in development of successful cancer therapy because
not all individual drugs are perfect for promoting apoptosis and achieving desirable
therapeutic outcomes. QCT, as previously mentioned, is a known autophagy inducer in
some glioblastoma cells (Kim et al., 2013), which may promote overall cell survival
during glioblastoma progression. Studies suggest that pairing QCT with another
compound to inhibit autophagy will heighten the therapeutic effects of QCT in
glioblastoma (Kim et al., 2013).
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While investigating the anti-cancer capabilities of QCT in glioblastoma, several
studies were conducted to gauge which drugs might pair best with QCT. So far the most
common pairing is QCT with TMZ, which is the most common chemotherapeutic drug
used for treatment of glioblastoma, as demonstrated in two recent studies (JakubowiczGil et al., 2013; Sang et al., 2014). Both studies emphasized the ability of QCT to inhibit
activities of HSP-27 and HSP-72. One of these groups showed that HSP-27 could
contribute to glioblastoma malignancy and its chemoresistance to TMZ (Sang et al.,
2014). It was suggested that increased HSP-27 phosphorylation might be an indicator for
TMZ chemoresistance. Their investigation also demonstrated that glioblastoma U251 and
U87 cell lines were insensitive to TMZ. However, QCT in combination with TMZ was
able to sensitize the glioblastoma cells to TMZ by inhibition of HSP-27 phosphorylation
and an increase in caspase-3 activity. The earlier study provided a more comprehensive
look at the molecular mechanisms of the treatment of combination of QCT and TMZ in
T98G cells (Jakubowicz-Gil et al., 2013). Even though some studies suggest autophagy
being a cell survival mechanism (Kumar et al., 2016), other studies imply that high
enough levels of autophagy may eventually lead majority of the cancer cells decide to die
by apoptosis (Jakubowicz-Gil et al., 2013). Both QCT and TMZ were able to induce
apoptosis in T98G cells, but neither drug increased levels of autophagy (Jakubowicz-Gil
et al., 2013).
Another synergistic study combined QCT and imperatorin for treatment of T98G
cells to further investigate the roles of HSPs in glioblastoma tumorigenesis (Badziul et
al., 2014). Imperatorin is a furanocoumarin and a phytochemical that can be used as an
analgesic, anti-inflammatory, anti-coagulant, and photosensitizing agent. It is also widely
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reported that imperatorin has potent anti-cancer properties. This study found that
combination of 50 µM QCT and 50 µM imperatorin caused more apoptosis than when
the drugs were used separately. The investigators also concluded that inhibition of HSP27 and HSP-72 was highly crucial in sensitizing glioblastoma cells to various forms of
treatment (Badziul et al., 2014).
Further study showed the consequences of the combination of QCT and sorafenib
in the treatment of astrocytoma MOGGCCM cell line and glioblastoma T98G cell line
(Jakubowicz-Gil et al., 2014). Sorafenib was originally developed to inhibit Raf kinase in
order to treat malignant brain tumors. However, clinical trials did not yield significant
therapeutic results. It was hypothesized that sorafenib in combination with QCT would
produce greater therapeutic effects than with sorafenib alone. This study observed that
sorafenib alone was a potent autophagy inducer in T98G cells, but not in MOGGCCM
cells. When QCT was used in combination with sorafenib, synergistic amounts of
apoptosis were seen in MOGGCCM cells. In the T98G cells, QCT showed little increase
in amounts of apoptosis when compared with sorafenib treatment alone. When levels of
expression of HSP-27 and HSP-72 were blocked by the short interfering RNA (siRNA),
the most commonly used RNA interference (RNAi) technology, both tumor cell lines
became increasingly more sensitive to QCT treatment (Jakubowicz-Gil et al., 2014).
Thus, all the above mentioned studies demonstrate how inactivation of HSPs through
QCT synergism can be a promising strategy in the development of alternative therapies
for making glioblastoma cells amenable to apoptosis.
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2.7 - QCT DELIVERY TO THE BRAIN
The most prevalent obstacle hindering the development of QCT-based
glioblastoma therapy is the inability of QCT to be efficiently delivered to the brain. This
issue contains two components: (1) poor bioavailability of QCT in the plasma and (2)
difficulty of many compounds including QCT to penetrate the BBB. Both of these
disadvantageous components are addressed by furthering the development of QCTloaded nanocarriers. A nanocarrier is a nano-sized compound that is used to carry various
compounds throughout the body. They are typically created by inserting a biologically
unstable compound (e.g., QCT) into a biologically stable structure (e.g., micelles,
liposomes, various polymers) (Liu et al., 2014). QCT makes an excellent candidate for
utilization of nanocarriers due to its low water solubility and rapid metabolic degradation
(Blasina et al., 2015).
Currently, many studies are being performed with the hopes of determining the
most efficient QCT-nanocarrier that utilizes efficient delivery and provides therapeutic
potency. First of all, in order for QCT to be a viable anti-cancer treatment, it must be
adequately distributed to the brain tissues. A study investigating the relationship between
QCT and cognition demonstrated that the intranasal administration of QCT-loaded
liposomes provided more efficient brain delivery than orally administered liposomes
(Priprem et al., 2008). This is due to the olfactory pathway bypassing the BBB and
providing QCT direct access to the brain. A very recent study expanded on the use of
lipid-based nanocarriers and their ability to deliver QCT to the brain (Kumar et al., 2016).
These investigators compared the use of nano lipidic carriers (NLCs) with solid lipid
nanoparticles (SLNs). NLCs utilize biocompatible compounds such as phospholipids,
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tocopherol acetate, and glyceryl behenate (a monoester of glycerin and behenic acid).
SLNs, on the other hand, utilize a solid lipid structure that is stabilized by various
emulsifiers. This study found that the use of lipid-based nanocarriers increased the
biodistribution of QCT to the brain 3.2 times (SLN) and 5.6 times (NLC) when compared
with the unaltered QCT (Kumar et al., 2016).
With oral administration being the most convenient form of drug delivery for
many types of medication, this route cannot be overlooked. Indeed, a recent study
investigated the ability of QCT-loaded cationic liposomes to assess distribution of QCT
throughout the body (Liu et al., 2014). Cationic liposomes are known to be advantageous
for oral administration of a drug due to their ability to interact with negatively charged
intestinal mucosa. This study found that these QCT-loaded cationic nanostructured lipid
carriers (QR-CNLC) were able to prolong exposure time in the gastrointestinal tract,
which subsequently improved intestinal absorption of the medication. QCT accumulated
in the lung, kidney, and liver. But insignificant amounts of QCT were found in the brain
tissue (Liu et al., 2014).
The next step after optimization of delivery is to ensure the therapeutic potency of
the nanoparticle-delivered QCT. A group of investigators examined the ability of QCT to
induce apoptosis in rat glioblastoma C6 cells in vivo following delivery of the PEG2000DPS-coated QCT nanoparticles to the rat brains (Wang et al., 2013). They were able to
conclude from their results that sustained QCT concentrations in rat brain tissues led to
significant amounts of apoptosis through the induction of intrinsic pathway. They
measured increase in cytosolic cytochrome c levels, which eventually led to increases in
caspase-9 and caspase-9 activities (Wang et al., 2013). In addition to all these studies that

26

we outlined here, many more studies need to investigate efficient methods for achieving
abundant biodistribution of QCT to the target tissues. Overall, significantly more research
must be conducted that can bridge the gap among QCT delivery, biodistribution, and
anti-cancer potential in glioblastoma in vivo.

2.8 - CONCLUSION
QCT is one of the most abundant dietary flavonoids that it is found in many fruits
and vegetables. QCT and many other flavonoids are known as potent anti-oxidants. But
over the past decade the anti-cancer potential of QCT has also been widely recognized. In
the treatment of glioblastoma, QCT has great potential in being an alternative second-line
therapy. It initiates high amounts of apoptosis in glioblastoma cells by activation of
caspase-9 and caspase-3, inhibition of HSPs, and down regulation of MAPK, PI3K/Akt,
and STAT3 signaling pathways. However, several hurdles must be overcome before QCT
can be used as a viable therapy for glioblastoma. Our current understanding of autophagy
and how it affects various cancer subtypes must be expanded. Some recent studies
suggest that QCT in combination with an appropriate chemotherapeutic agent can
circumvent autophagy and act synergistically to promote induction of apoptosis in
different glioblastoma cells. Also an efficient in vivo QCT delivery method must be
developed to penetrate BBB and sustain sufficient QCT concentrations in the brain in
order to combat progression of glioblastoma growth. Despite the long road of discovery
and delivery that await, we think that QCT is a promising flavonoid that in a synergistic
combination has the high potentials to improve the treatment outcomes in the near future
in many patients who are afflicted with glioblastoma.
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CHAPTER 3

SYNERGISTIC EFFECT OF QUERCETIN AND SODIUM BUTYRATE
IN INHIBITION OF AUTOPHAGY AND INCREASE IN APOPTOSIS IN
RAT AND HUMAN GLIOBLASTOMA CELLS
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ABSTRACT
Glioblastoma is the most common and aggressive primary brain tumor, with a
prevalence of approximately 20,000 new cases per year in the United States and a 3-year
survival rate of just 2%. Surgery alone does not cure glioblastoma because the diffuse
residual tumor cells, which are never eliminated by surgery, eventually cause recurrence
of the tumor. Due to the poor prognosis and limited current treatment options for this
malignant disease, new therapeutic strategies must be investigated. Nutrient deficiency
and hypoxia in the tumor foster autophagy, which acts as a process of recycling of
building blocks of cells to promote survival and proliferation of glioblastoma cells.
Different molecular attributes contribute to prevention of apoptosis in glioblastoma cells.
We explored the synergistic efficacy of quercetin (QCT) and sodium butyrate (NaB) in
rat C6 as well as in human T98G and LN18 glioblastoma cell lines using Trypan Blue
dye staining. The results indicated that 25 µM QCT and 1 mM NaB exhibited the
greatest synergistic effect on apoptosis. The synergistic effect of QCT + NaB was
measured in inhibition of autophagy in the 48-h serum-starved glioblastoma cells using
acridine orange staining. We found down regulation of autophagy due to treatment with
combination of drugs, when compared with a single drug. Next, the morphological
feature of apoptosis was measured by Wright Staining, which showed occurrence of
approximately 50% apoptosis in each cell line; with the greatest impact being on T98G.
Exposure of cell membrane phospholipids, an early biochemical feature of apoptosis, was
quantified via Annexin V staining and flow cytometry. We found that glioblastoma cells
treated with QCT + NaB increased induction of apoptosis (between 50 and 60%),
whereas the single treatment caused less induction of apoptosis (between 20 and 40%).
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Our study is designed for understanding the morphological and biochemical features of
inhibition of autophagy and enhancement of apoptosis in the serum-starved glioblastoma
cells due to synergistic effect of QCT and NaB.

3.1 - INTRODUCTION
Glioblastoma Multiforme is the most common and aggressive primary brain
tumor with a median survival time with treatment of 15 months. Currently there is no
known cure. Modern treatments include simultaneous chemotherapy and radiotherapy
with second line treatments, such as Bevacizumab, having little impact on prognosis.
Since GBM has such a bleak prognosis, continued alternative therapy development is
crucial. Today, two widely pursued treatment development avenues exist for GBM,
immunotherapy and synergism. This study focuses on analyzing the synergism between
the bioflavonoid quercetin and histone deacetylase inhibitor sodium butyrate and their
effects on apoptosis and autophagy.
Drug synergism is a common therapeutic avenue to treat complicated pathologies
such as hypertension, diabetes, and cancer. Many conventional chemotherapeutic agents
prove to be unsuccessful in many cancer treatments due to the molecular and genetic
variations in cancer subtypes, leading to eventual drug resistance (Jang et al., 2015). To
combat these poor outcomes, methods such as targeted nanoparticle delivery, monoclonal
antibodies, and drug synergism are actively being developed. Although finding a suitable
synergistic drug combination for a certain disease has been difficult to ascertain, when
that combination is found it can give a detailed mechanistic view into disease progression
and drug interactions (Yin et al., 2014). Synergistic drug combinations can also provide
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highly specific treatment avenues with lower overall side effects. Many chemotherapies
have proven to be highly cytotoxic with unspecific cellular targets. Temozolomide
(TMZ), the most common first-line chemotherapy treatment for GBM, is an orally
delivered DNA alkylating agent that eventually induces GBM chemo-resistance (Winkler
et al., 2014). Synergism aims to lower the overall chemotherapy drug dose by combining
the therapy with a less cytotoxic drug while simultaneously increasing the anticancer
effects on a patient’s specific cancer subtype (Yin et al., 2014).
A 2014 clinical study conducted on GBM patients showed that TMZ
administration in conjunction with chloroquine synergistically increased the
chemosensitivity of GBM to TMZ by chloroquine-induced autophagy downregulation
(Golden et al., 2014). Autophagy in cancer is generally considered to be a protective
mechanism, but can also inhibit growth during tumor development (Yang and Klionsky,
2010). Similarly to the Golden et al. study, this study aims to study the synergism
between QCT and NaB on glioblastoma by measuring its impact on apoptosis and
autophagy. QCT, a known autophagy upregulator, is also a potent anti-cancer agent.
NaB is a HDACi that has been shown to induce autophagy in various forms of cancer,
but little investigation has been performed in GBM. More importantly, NaB has the
potential to make epigenetic changes in GBM to allow QCT to further potentiate its anticancer effects (Yurtsever et al., 2013).
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3.2 - MATERIALS AND METHODS
Reagents. HycloneTM RPMI-1640 Medium, HycloneTM trypsin-EDTA, phosphate
buffered saline (Fisher Scientific), fetal bovine serum (BioABChem),
penicillin/streptomycin (cellgro®), 0.4% trypan blue solution (Sigma Aldrich), KwikDiffTM Solution #1, Kwik-DiffTM Solution #2, Kwik-DiffTM Solution #3, acridine orange
(InvitrogenTM), Annexin V-FITC (BD Biosciences), propridium iodide (BD Biosciences),
Annexin V buffer solution (BD Biosciences), caspase-3 polyclonal antibody (Santa Cruz
Biotechnology), LC3B monoclonal antibody (Cell Signaling Technologies), cleaved
PARP-1 monocloncal antibody (Cell Signaling Technologies), survivin monocloncal
antibody (Santa Cruz Biotechnology), Bcl-2 polycloncal antibody (Santa Cruz
Biotechnology), Bax polycloncal antibody (Santa Cruz Biotechnology), β-Actin
polycloncal antibody (Santa Cruz Biotechnology), 4X Laemmli Sample Buffer (BioRad), ClarityTM Western ECL Substrate (Bio-Rad), quercetin (Sigma Aldrich), sodium
butyrate (Sigma Aldrich).
Cell Culture. C6 rat glioblastoma cells were provided by ATCC # CCL-107.
T98G human glioblastoma cell line was provided by ATCC # CRL-1690. LN18 human
glioblastoma cell line was provided by ATCC # CRL-2610. All cell lines were grown in
HycloneTM RPMI-1640 medium with 10% fetal bovine serum and 1%
penicillin/streptomycin. Serum starved samples were grown in HycloneTM RPMI-1640
medium with 0% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S). Cells
were grown in a humidified incubator at 37°C and 5% CO2.
Experimental Procedure. Appropriate amounts of GBM cells were plated on
either 100x15 mm petri dishes or 6-well suspension culture plates according to each
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experimental protocol. Samples were grown for 24 hours in RPMI-1640 medium
containing 10% FBS and 1% P/S for 24 hours to allow cell adhesion and recovery to
occur. Samples were then serum starved for 24 hours with RPMI-1640 medium
containing 0% FBS and 1% P/S for 24 hours in order to induce autophagy. Samples were
then treated for 24 hours with either 25 µM QCT, 1 mM NaB, or a combination of 25 µM
QCT + 1 mM NaB. Control samples were grown in replenished serum-starve medium
(RPMI-1640 w/ 0% FBS + 1% P/S). Samples were then tested with the appropriate
experimental protocols.

Figure 3.1: A visualization of the cell culture protocol for all experiments conducted
throughout the study.
Statistical Analysis. All experiments were performed with a minimum of n ≥ 3.
Standard error was calculated with the equation: Standard Error =
StDev(n1,n2,..nx)/Sqrt(n). Only upward error bars were used because the lower error bars
are assumed. Statistical significance was calculated via One-way ANOVA and p-values
were calculated by a Fisher post-hoc test with the Minitab Express software.

Trypan Blue Exclusion Assay
The first step in this study is to determine the cell viability for each GBM cell line
at varying doses of both QCT and NaB. In order to do this, a trypan blue exclusion assay
(TBEA) was performed. Trypan blue is a diazo dye characterized by its impermeability
to viable cells. It is used in clinical settings by opthamologists during anterior segment
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surgeries such as corneal transplants (Jhanji et al., 2011). Laboratory testing for cell
viability is just as profound. TBEA for cell viability uses the premise that dead or dying
cells lose their membrane integrity, which allows the dye to infiltrate the cells. The
samples can then be read under a microscope and counted in order to determine cell
viability by using the formula:
Viable cells (%) = 100 - (# of apoptotic cells ÷ total # of cells × 100)
Despite its simplicity and short experimetal timeframe, TBEA has two caveats (Strober,
1997). This test assumes that every cell with a permeable membrane is apoptotic, which
is sometimes not the case (Cooper & McNeil, 2015). Another issue is that data collection
relies on the precision and accuracy of manual experimenter quantification . But despite
these downfalls, TBEA is a simple, reliable, and efficient method for determining cell
viability.
The TBEA was used in order to calculate synergism. Synergism is when two
separate compounds produce an effect that is greater than the sum of their individual
effects. This concept identified the most ideal doses of QCT and NaB to be determined
in order to clearly demonstrate the impact of the interaction of these two drugs on GBM
cells. Cell viability data was inputted into the program CompuSyn (ComboSyn,
Paramus, NJ) to calculate the combination index (CI) value of QCT and NaB at varying
dosages. A CI value is a concept developed by Paul Talalay and Ting-Chao Chou in
1984 that aims to quantify synergism. They developed an equation called the medianeffect equation that utilizes concepts from the Henderson-Hasselbalch equation, Hill
equation, Michaelis-Menten equation, and Scatchard equation to normalize dose-effect
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values to quantify synergism (Chou, 2010). The mathmatical formulas for calculating
synergism is as follows:

fa/fu = (D/Dm)m
Median-Effect Equation

𝑛

1/m

Dx = Dm[fa/(1-fa)]

CI = ∑

(D ) 𝑗

𝑗=1 (Dx)j

D = Dose, fa = fraction affected, fu = fraction unaffected, Dm = median-effect dose, m =
slope or kinetic order
A CI value less than 1 indicates synergism, with doses being more synergistic as their CI
value approaches zero. CI values greater than 1 indicate antagonism, which means the
combined drugs are working against each other. A CI value equal to 1 indicates the
drugs are additive (Chou, 2010). The doses used were QCT 12.5 µM, QCT 25 µM, QCT
50 µM, QCT 100 µM, NaB 1 mM, NaB 3 mM, NaB 5 mM, NaB 8 mM, and
combinations of each single dose.
GBM cell lines C6, T98G, and LN18 were grown and treated using the previously
described experimental protocol. The samples were harvested via trypsinization for two
minutes. Trypsin was neutralized by adding 1 ml RPMI-1640 10% FBS 1% P/S medium
to 0.5 ml trypsin. Samples were spun at 3000 RPM for 4 minutes and washed twice with
1X phosphate buffered saline (PBS). One part cell suspension (10µl) was mixed with
one part 0.4% trypan blue (10µl) for 3-5 minutes at room temperature. Then 10µl of cell
+ trypan blue mixture was added to a hemocytometer and read at a 10X magnification.
Samples were counted and calculated according to the previously described equation and
plotted on Microsoft Excel 2016.
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Figure 3.2: Trypan blue exclusion assay with T98G cells drugged with QCT 25 µM +
NaB 1 mM visualized at 10X on a hemocytometer using an Olympus BX53 microscope.
Wright Stain
Wright staining was used to visualize the morphological signs of apoptosis in
GBM cells. The technique is more commonly used to stain peripheral blood smears and
bone marrow, but adequately stains most types of cells. Eosin dyes are used in histology
to stain cytoplasmic components such as amino acids and proteins. Methylene blue is a
basic thiazine dye that is able to stain astrocytic nuclei purple. Wright Staining uses a
combination of eosin (red) and methylene blue dyes to give a multi-dimensional picture
of cell morphology (Yue, 2014).
This technique was utilized to visualize the morphological changes that occur
when GBM cells are underoging apoptosis. The most prevalent change that occurs to
apoptotic cells is condensation and fragmentation of the nucleus. One of the greatest
hallmarks in the apoptosis molecular pathway is the caspase activation cascade. After the
apoptosome is formed through the intrinsic mitochondrial apoptosis pathway, caspase-9
activates caspase-3 (Taylor and Ray, 2017). Caspase-3 activation then causes cleavage of
nuclear structural proteins, such as lamin, which promps the degredation of the nucleus
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structure. Early apoptosis shows the nucleus forming a crescent shape, followed by
complete nuclear condensation in the later stages of apoptosis. It is important to note that
cell membrane integrity is still in tact. This is a process called karyorrhexis (Ziegler &
Groscurth, 2004).

Figure 3.3: Wright staining of T98G GBM cells dosed with QCT 25 µM + NaB 1 mM.
(A) A normal, non-apoptotic cell (B) Cell undergoing early apoptosis showing a crescent
shaped nucleus (C) Late apoptotic cells showing complete nuclear condensation and cell
shrinkage.

Another morphological sign of apoptosis is cellular membrane degredation and
blebbing. Blebbing is a protrusion of the cell membrane caused by degredation of
membrane structural proteins such as actin and β-catenin; along with gelsolin, Gas2, and
PAK2, which help maintain organization and attachment of the cytoskeleton. Due to
membrane degredation, the cell will begin to lose volume during the middle to late
apoptotic stages. Blebbing will occur due to the increased pressure of the cytoplasm
caused by the membrane shrinkage. Decreased membrane integrity will allow
protrusions of cytoplasm to appear (Ziegler and Groscurth, 2004).
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As blebs begin to separate, nuclear fragmentation will start to initiate. These
fragments have lost membrane integrity and will expose intracellular contents to the
external environment. Under most circumstances, these intracellular components will be
phagocytosed; thus, not causing an inflammatory response (Ziegler and Groscurth, 2004).
Phagocytosis is initiated by the externalization of phosphatidylserine, which is a
glycerophospholipid that resides on the internal side of the cellular membrane. Upon
initiation of apoptosis, the enzyme flippase in inactivated which allows for the
externalization of phosphatidylserine (Verhoven et al., 1995). Phosphatidylserine signals
macrophages to phagocytose the apoptotic cells. If apoptotic cells are not phagocytosed
by the host immune system, their degradation patterns will begin to resemble necrosis.
Necrosis is a form of cell death that does not undergo the normal apoptosis
mechanism. It is often initiated by factors such as high heat or a toxic environment.
Morphologically the greatest difference between apoptosis and necrosis is necrotic cells
lose membrane integrity in the very early stages of cell death. Necrotic cells can be
distinguished by massive swelling of the cell, caused by polar molecules passing through
the porous cell membrane. Necrotic cells are often not quantified when measuring
amounts of apoptosis in a sample due to it being a form a cell death not caused by the
desired drug treatments (Ziegler and Groscurth, 2004).
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Figure 3.4: Image D shows cell membrane blebbing in T98G GBM cells treated with a 24
hour dose of QCT 25 µM. Image E shows nuclear fragmentation in T98G GBM cells
treated with a 24 hour dose of NaB 1 mM. Image F shows necrosis in T98G GBM cells
in a 48 hour serum-starved control sample.

Approximately 100,000-300,000 C6, T98G, and LN18 GBM cells were grown in
preparation for wright staining using the previously mentioned experimental protocol in
6-well plates. Upon sample readiness, treated RPMI-1640, 0% fetal bovine serum (FBS),
1% penicillin/streptomycin (P/S) medium is removed by a Pasteur pipette with careful
consideration taken to not aspirate free-floating cells. Immediately after medium
removal, 1 ml of Kwik-DiffTM Solution #1 is added to each well for 25 seconds in order
to fixate the cells to the plates. Solution #1 is removed by a Pasteur pipette and 1 ml
Kwik-DiffTM Solution #2 is added to each well for approximately 20 seconds. Solution
#2 is removed via Pasteur pipette and approximately 0.7 ml Kwik-DiffTM Solution #3 is
added to each well for approximately 20 seconds and then removed with a Pasteur
pipette. Samples are then washed with 1 ml dH2O to remove any excess dye. The
samples are immediately read on an Olympus BX53 microscope at 10X magnification.
Images were taken using an Olympus SC30 camera mounted on the BX53 microscope.
Apoptosis was quantified by manually counting approximately 300 cells, differentiating
between apoptotic and non-apoptotic. Apoptotic cells were characterized by the previous
described criteria. Percentage of apoptosis in each sample was calculated by:
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Percent Apoptosis (%) = [# of Apoptotic Cells ÷ Total # of cells] x 100
These results were then plotted in Microsoft Excel 2016. Each experiment was
performed in triplicate.
Annexin V
A common and efficient way to quantify apoptosis in a cell population is the
Annexin V test. It utilizes a dual Annexin V-FITC + Propidium Iodide (PI) stain to
determine the physiological state of samples undergoing a form of cell death. Annexin V
is a Ca2+ dependent phospholipid binding protein that has a high affinity to
phosphatidylserine, a cellular membrane phospholipid that becomes externalized in the
early stages of apoptosis. PI is a fluorescent dye that is unable to permeate viable cell
membranes. It is commonly used in flow cytometry of fluorescent microscopy to
evaluate whether a cell is live, apoptotic, or necrotic. A combination of both Annexin VFITC and PI paints a clear picture of the stages of cell viability in a sample population
(Hingorani et al., 2011).
A flow cytometer is a powerful tool that is used to measure many different
properties of a cell population. It is based off the premise of shooting a laser at an
individual cell, then analyzing the resulting light scatter patterns. Flow cytometers have
the ability to measure any property of a cell, as long as the fluorescent probes are
conjugated to bind to the desired property. This versatility allows flow cytometers to
measure anything from DNA, RNA, cytoplasmic acidity, membrane permeability,
various proteins, receptors, and many more. In addition, multiple fluorescent probes can
be analyzed simultaneously on the same cell. This allows for precise categorization of
individual cells into a maximum of 4 subpopulations displayed on a biaxal graph.
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Figure 3.5: This is a flow cytometry graph of C6 cells treated for 24 hours under 48 hour
serum starvation with QCT 25 µM + NaB 1 mM. The graph is divided into 4
subpopulations: A1 = AnnexinV-/PI+, A2 = AnnexinV+/PI+, A3 = AnnexinV-/PI-, A4 =
Annexin V+/PI-. Each graph represents 10,000 cells.

These four subpopulations display cells in different physiological states.
Quadrant A3 represents AnnexinV-/PI-, which means neither Annexin V or PI dyes
bound to or penetrated the cell. This indicates that phosphatidylserine has not been
externalized and the cell membrane is fully intact; thus, determining that the cells are
fully viable. Quadrant A4 represents AnnexinV+/PI- cells, which means Annexin V is
bound to those cells, but PI was unable to penetrate the cell membrane. This indicates
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that the cells are undergoing the early stages of apoptosis. Quadrant A1 shows cell
populations that are AnnexinV-/PI+, meaning that PI was able to penetrate the cell
membrane, but Annexin V did not bind to the cell. This subpopulation shows cells that
were mechanically damaged, usually caused by experimenter error when handling the
samples. Quadrant A3 represents cells that are AnnexinV+/PI+, meaning that both
Annexin V bound to the cell and PI was able to penetrate the deteriorating membrane.
The cells in this subpopulation are either necrotic, in the late stages of apoptosis, or dead.
Since both necrotic cells and late apoptotic cells are able to bind Annexin V and PI,
differentiating them in this subpopulation is not possible.
When performing the Annexin V test, all samples were grown and treated
according to the previously described experimental protocol. Approximately 500,000
cells were grown in 6-well plates for 24 hours before serum starvation and treatment
began. At the time of collection, samples were stained according to the BD Biosciences
standard protocol. Treated RPMI-1640 medium, 0% FBS, 1% P/S was removed from
each 6-well plate. 500 µl of 1X trypsin was added to each plate for 3 minutes in order to
reduce cell adhesion. The trypsin was then neutralized with 1 ml RPMI-1640, 10% FBS,
1% P/S medium and the cells were gently pipetted into 1.5 ml microcentrifuge tubes.
Samples were spun at 3,000 RPM for 4 minutes. Trypsin + RPMI-1640 was removed
from the samples via Pasteur pipette and each sample was washed with 200 µl Annexin V
binding buffer. The 200 µl Annexin V binding buffer was removed via Pasteur pipette
and replaced with fresh 100 µl Annexin V binding buffer. The cells were then evenly
distributed throughout the binding buffer by gentle pipetting. 5 µl Annexin V-FITC and
5 µl PI was added to each sample, and incubated in the dark at RT for 15 minutes. After
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the incubation has completed, 400 µl Annexin V binding buffer was added to each
sample. The samples were then transferred to flow cytometry tubes for analysis.
In order to configure the Cytomics FC 500 Flow Cytometer to read each cell line
accurately, three control samples were prepared: (1) Blank sample – untreated 48 hr
serum-starved cells + 500 µl Annexin V binding buffer (2) FITC – untreated 48 hr serumstarved cells + 500 µl Annexin V binding buffer + 5 µl Annexin V-FITC (3) PI –
untreated 48 hr + 500 µl Annexin V binding buffer + 5 µl PI. These sample
measurements allowed for specific quadrant setup according to the properties of each cell
line. Graphs were generated with PI staining on the Y-axis and Annexin V-FITC on the
X-axis.

Figure 3.6: The three loading controls used to set up the quadrants and compensation for
C6 Annexin V. The C6 GBM cells shown here are untreated and serum starved for 48
hours. Quadrants were drawn based on the populations of cells from each stain.
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Figure 3.7: This figure depicts untreated 48 hr serum starved FITC-only stained C6,
T98G, and LN18 cell measurements in the Cytomics FC 500 Flow Cytometer.

The vertical division between quadrants A1 & A2 and A3 & A4 was determined
by two criteria. Firstly, the line was drawn at the division between the viable and early
apoptotic cell populations. But in many samples, the division between both populations
was not well defined. Therefore, the second criteria is based off the data collected with
trypan blue and Wright Staining. Those tests showed approximately 10% apoptosis in all
control samples under 48 hour serum starvation across all cell lines. In staying consistent
with that trend, the vertical quadrant line was drawn in accordance to the previously
measured basal levels of apoptosis.
The horizontal quadrant line remained fairly consistent across all cell lines. The
AnnexinV-/PI+ cells had a more clearly defined border than the AnnexinV+/PI- cells.
This may be due to early apoptotic cells having variable amounts of phosphatidylserine
externalized, which would cause cells to increase steadily across the X-axis with less
clearly defined population borders. Mechanically damaged cells would continue to allow
similar amounts of PI to penetrate the membrane until the cell becomes completely
saturated, thereby generating a more well-defined population border.
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Figure 3.8: Flow cytometry data showing C6, T98G, and LN18 untreated cells under 48
hr serum starvation. This is demonstrating the clearly defined borders of AnnexinV-/PI+
cells compared to AnnexinV+/PI- cells in figure 3.1.

Acridine Orange
Acridine orange (AO) staining is a multi-faceted approach to visualize variations
in the cell cycle. AO is a basic cell-permeable dye that has been widely used in
cytochemistry by staining DNA and RNA (Thomé et al., 2016). It binds to dsDNA
through intercalation and binds to ssDNA/ssRNA through electrostatic interactions.
Under a fluorescent microscope, AO emits green fluorescence at 530 nm and red
fluorescence at 640 nm (Lauretti et al., 2003). Another common application for AO dye
is visualization of acidic vesicular organelles (AVO) produced by autophagy. AO is able
to penetrate the cells and emit a bright red fluorescence when interacting with a high H +
environment. Since the basic AO dye is protonated when exposed to low pH, it is unable
to cross the cell membrane and exit the cell (Pierzynska-Mach et al., 2014).
Autophagy is a cellular process characterized by the formation of
autophagosomes. Autophagosomes are formed during microautophagy, where parts of
the cytosol and mitochondria are engulfed and eventually linked with an autolysosome to
eventually be degraded. Autophagy is considered an essential cellular process that
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maintains a baseline level of activity in order to recycle old organelles and initiate protein
turnover. However, autophagy also acts as a cellular protection mechanism when cells
are exposed to stressful environments such as high heat, oxidative stress, and many drug
treatments (Yang and Klionsky, 2010).

Figure 3.9: Acridine Orange staining performed on C6 GBM cells under normal growing
conditions with RPMI-1640, FBS 10%, P/S 1% medium. Bright-red fluorescent cells are
showing the presence of AVOs formed by autophagy at 20X magnification. Cells in the
center of the cell-cluster have a higher incidence of stress-induced autophagy due to
inherent nutrient starvation, while cells on the outside of the cluster show basal-levels of
autophagy caused by routine cell maintenance.

In cancer research, autophagy has been a rigorously investigated topic due to its
inherent cellular protection properties during cancer progression. Figure 3.9
demonstrates how cells residing in the center of a tumor become autophagic due to
environmental stressors caused by the high density of cells. Many anti-cancer drugs,
including QCT, are well-known autophagy upregulators. These factors contributing to
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the increased autophagy in cancer cell populations can hinder the ability for many anticancer treatments. This concept prompted the investigation of autophagy in conjunction
with the apoptotic properties of QCT + NaB in GBM.

AO Fluorescence Microscopy
Acridine orange was used to visualize autophagy in C6, T98G, and LN18 cell
populations. Cells were grown in 6-well plates with microscope coverslips placed inside
each well. Approximately 1x106 cells were plated onto each coverslip and the cells were
grown for 24 hours in RPMI-1640, 10% FBS, 1% P/S in 37°C, 5% CO2 conditions.
Once the samples were ready for analysis, the medium was removed via Pasteur pipette,
taking careful consideration to not aspirate any samples. The cells were then fixed with
methanol for 20 seconds in order to ensure adherence to the coverslips. The cells were
then washed with 1 ml 1X PBS two times. AO dye was added to each well at a
concentration of 1 µg/ml and incubated at 37°C for 15 minutes. AO stain was then
removed from the wells and the coverslips were placed on glass microscope slides. The
samples were visualized on the LeicaDM 2500 fluorescent microscope with a Texas Red
filter. All samples were photographed at 20X and 40X. The data figures were generated
using 40X photos to better visualize individual cell AVOs.

AO Flow Cytometry
It is common practice to use acridine orange with a flow cytometer to quantify
autophagy. A 2011 study described acridine orange stained AVOs show bright red
fluorescence (650 nm) in the FL-3 channel on a flow cytometer (Mohan et al., 2011).
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Using this concept, autophagy was quantified by using a Cytomics FC 500 Flow
Cytometer. Since the quantity of AVOs increases along the FL-3 axis and the amount of
AVOs correlate with the amount of autophagy in a population, then the quantity of cells
in FL-3 directly measured the level of autophagy in a sample. First, cells were grown
according to the previously mentioned experimental protocol in 6-well plates. At the
time of collection, treated medium was removed and replaced with 500 µl trypsin. The
trypsin was then neutralized with 1 ml RPMI-1640 10% FBS 1% P/S medium. Cells
were gently collected into 1.5 ml microcentrifuge tubes and centrifuged at 3,000 RPM for
4 minutes. The trypsin + RPMI was removed with a Pasteur pipette and washed once
with 1X Annexin V Binding Buffer. The 1X Annexin V Binding Buffer was removed
and 200 µl 1 µg/ml AO dye was added to each microcentrifuge tube. The cells were
incubated for 15 minutes at room temperature. The AO dye was then removed and
replaced with 500 ml 1X Annexin V Binding Buffer. The samples were then transferred
to flow cytometry tubes and measured on the FC 500 Flow Cytometer. To quantify the
amount of AVOs present in each sample, the density of FL-3 was measured. Measured
samples included serum starved populations: (A) 0 hours (B) 12 hours (C) 24 hours, and
also included Control, QCT, NaB, and QCT + NaB. All samples were normalized to the
baseline measurement taken at 0 hour serum starvation. In theory, these samples should
have the lowest amount of autophagy amongst every sample due to them being grown in
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ideal conditions.

Figure 3.10: A plot of FL-3 on a FC 500 Flow Cytometer on T98G cells. 0 hr samples
represents cells that have not been exposed to serum starvation; therefore, should be
showing the basal level of autophagy for that cell line.

The data was originally graphed on a histogram showing the distribution of cells
on the FL-3 channel. That histogram also displayed a number correlating with that
density. That number, however, should not be mistaken for the percentage of autophagic
cells. All cells go through a minimal amount of autophagy as a part of routine cellular
maintenance (Yang & Klionsky, 2010). Therefore, just because a cell contains an AVO,
does not mean they are completely autophagic. Because of this, cells grown in ideal 10%
FBS conditions (0 hr) were considered to have 0% autophagy. All samples were then
normalized to the 0 hr samples. Each sample was conducted in triplicate and the
averages of all three samples were used to form a mean. Standard error was then
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calculated with the equation: StDev(Samples)/Sqrt(3). This number was used to make the
upper error bar on the bar graphs made in Microsoft Excel 2016.

Western Blotting
Western blotting is the most commonly used technique used to visualize various
proteins in a cell population. It utilizes a multi-step antibody binding process that allows
for specific binding and visualization for individual proteins. This method allows for the
molecular pathway for apoptosis induced by QCT + NaB in GBM to be uncovered.
Samples were grown according to the previously described experimental protocol.
Approximately 2x106 cells were plated onto 100x15 mm petri dishes and grown for 2448 hours. T98G and LN18 cells were grown for 48 hours to ensure adequate cell
adhesion and recovery, while C6 was only grown for 24 hours due to its rapid growth
rate.
Sample Preparation: When the samples were ready for collection, they were
washed with 1.5 ml cold PBS and scraped into 1.5 ml microcentrifuge tubes. The
samples were then spun at 10,000 RPM for 5 minutes. Then 200 µl RIPA lysis buffer
was added to each tube. The samples were vortexed for 15 seconds and left on ice for 20
minutes to ensure complete cell lysis. The tubes were then centrifuged again at 10,000
RPM for 5 minutes and 200 µl supernatant was removed and placed into new 1.5 ml
microcentrifuge tubes.
Protein Normalization: The importance of protein normalization is to ensure that
equal quantities of protein are loaded into each well. A samples of 2 mg/ml BSA was
diluted into the concentrations: 2 mg/ml, 1mg/ml, 500 µg/ml, 250 µg/ml, 125 µg/ml, 62.5
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µg/ml, 31 µg/ml, 16 µg/ml. 2 µl of each diluted sample of BSA and 2 µl of each sample
were added to the wells of a 96-well plate according to the following template:

Figure 3.11: A schematic showing the layout of the 96-well plates used to normalize
western blot samples.
The BSA standards and samples were then stained with 200 µl Coomassie PlusTM Protein
Assay Reagent. When in contact with protein, the Bradford reagent stains blue and can
be read at 595 nm to determine the quantity of protein in a sample. After waiting 5
minutes, the 96-well plate was read on a BioTek µQuant spectrophotometer at 595 nm.
The results were then used to calculate the total amount of 4X Laemmli Buffer, βmercaptoethanol (β-ME), and sample should be added to each gel electrophoresis well.
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The calculations were completed as follows:

Figure 3.12: A representation of the mathematical process behind normalizing the
Western Blot protein samples.
By measuring the absorbance of each known concentration of protein, a standard curve
can be formed. This standard curve allows for the calculation any protein concentration
based off its absorbance. The absorbances of each sample are also measured and plugged
into the y=mx+b equation given by the standard curve. This calculation gives the protein
concentration in µg/ul. The samples were then diluted in 3:1 Sample:4X Laemmli buffer
+ β-Me. The purpose of the Laemmli buffer + β-Me is to denature all proteins and give
them an overall negative charge, reduce intra and inter-molecular disulfide bonds, and
visualize the proteins as they are loaded and run through the SDS-PAGE gel. The
samples were then heated at 95°C in a water bath for 12 minutes. At this point the
samples were either loaded onto a gel or stored at -20°C for up to 6 months. When the
samples were ready to be loaded onto the gel, sample volumes were calculated so 20 µl
of protein was in each well.
SDS-PAGE: The samples were then run a through Sodium Dodecyl Sulfate
Polyacrylamide Gel Electrophoresis (SDS-PAGE) gel in order to separate the sample
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proteins based off size. The theory behind SDS-PAGE is that all samples have been
denatured, thereby elimiating the protein tertiary structure. The sample loading buffer
has also given all proteins the same negative charge. The purpose behind these property
changes is to eliminate all variables between the proteins besides size. The protein
samples were then inserted into 4-20% Mini-PROTEAN® TGXTM Precast Protein Gels
from Bio-Rad according to the previously calculated sample-specific volumes in order to
maintain the 20 µg of protein per well standard. The gels were then run at 120 V in a
custom made running buffer until the bottom band of Laemmli buffer reached the end of
the gel.
Western Blotting: After the SDS-PAGE gels were completed, the gels were
transferred onto a Millipore PVDF membrane via wet transfer on the Bio-Rad MiniPROTEAN® Tetra System. The membranes were either transferred overnight at RT with
59 mA or transferred in 1 hr at 4°C at 90 V. In order to verify that all proteins were
transferred from the gel to the membrane, a Ponceau S stain was performed, then
immediately washed with Phosphate Buffered Saline + .01% Tween-20 (PBST) until the
red bands were removed. The membrane was then cut according to the size of the protein
of interest. The membrane was then blocked with 1X PBST + 5% milk for 1 hour. This
ensures that the antibodies do not bind anywhere on the PVDF membrane except their
target antigen. The blocking buffer was then discarded and the membrane washed 1X
with PBST. The primary antibody, which was diluted in PBST + 5% milk, was added to
the PVDF membrane and incubated at 4°C overnight. The purpose of the primary
antibody is to bind to the protein of interest. Primary antibodies are grown in an animal
(e.g. rabbit, mouse) and made to conjugate to a specific protein (e.g. caspase-3). Slower
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primary antibody incubation ensures more precise binding to the target protein, as
opposed to room temperature incubation for a shorter time. The next day, the primary
antibody is removed and stored at -20°C, and the membrane was washed 5x with PBST
for 5 minutes per wash. After adequate washing, the secondary antibody was added to
the membrane for 30 minutes. The purpose of the secondary antibody is to bind to all
antibodies belonging to a certain animal and be conjugated with a flourochrome such as
horseradish peroxidase (HRP). For example, if a rabbit anti-caspase-3 antibody was used
as the primary antibody, then a goat anti-rabbit secondary antibody must be used. All
primary antibodies were made with a dilution of 1:1,000 while all secondary antibodies
were made with a 1:10,000 dilution. After 30 minutes, the secondary antibody was
removed and the membrane was washed 5x with PBST for 5 minutes per wash. The next
step is to add ClarityTM Western ECL Substrate, containing a peroxide solution and
luminol/enhancer solution. Equal quantities of these solutions were added to the
membrane and incubated at room temperature for 5 minutes. This binds to the HRP and
produces a light signature that can be visualized with x-ray film. After 5 minutes the
membranes were exposed to USA Scientific Blue Autoradiography & Western Blotting
Film for 10 seconds – 15 minutes, depending on the light intensity of the sample. The
films were then developed and scanned on a Epson Perfection V500 Photo Scanner.

Table 3.1 - Western Blotting Buffers
1X Running Buffer
1X Transfer Buffer
1) Tris – 3 g
1) Tris – 3 g
2) Glycine – 14.4 g
2) Glycine – 14.4 g
3) SDS – 1 g
3) Methanol – 200 ml
4) dH2O – fill to 1 L
4) dH2O – fill to 1 L
Table 3.1: A table showing the ingredients going into the custom-made western blot
buffers.
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3.3 - Results & Discussion
Trypan Blue
Trypan blue staining was performed on C6 cells to find the most synergistic drug
combination, which is represented by the lowest CI value. Only C6 was used when
determining the CI value because the next stage of experimentation would include using
QCT and NaB in a rat model; therefore, having the most synergistic drug combination for
a rat model was the most desired. Further experimentation was done with Wright
Staining and trypan blue staining to ensure that T98G and LN18 cells acted in similar
ways to C6 in terms of the amount of apoptosis induced with each drug combination.
The data showed that QCT 25 µM + NaB 1 mM had the greatest amount of
synergism with a CI value of 0.1746 (Table 3.2). The combination that had the next
highest amount of synergism was QCT 25 µM + NaB 3 mM with a CI value of 0.2056
(Table 3.2). This alludes that the data is meaningful to the point where our chosen
dosage is in the correct range. QCT was shown to have the greatest impact on apoptosis,
while NaB had little effect. This conclusion is also supported with the apoptosis data
collected from Wright Staining. As the concentration of QCT increased, the QCT + NaB
combination became less synergistic. QCT 100 µM samples had CI values ranging from
0.38409 – 0.736, indicating that NaB was unable to act in a meaningful manner with such
high QCT concentrations.
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Figure 3.13: A line graph displaying the cell viability results from trypan blue staining on
C6 GBM cells. This data was used to determine the most synergistic drug combination
between QCT and NaB. QCT concentrations ranged from 12.5 µM – 100 µM. NaB
concentrations ranged from 1 mM to 8 mM. The cell viability values were then entered
into the CompuSyn software and the CI values were calculated. QCT 25 µM + NaB 1
mM was the combination found to be the most synergistic.

The greatest benefit to this technique is the low cost and ease of use. However, this
technique also contains some downfalls that must be taken into consideration when
interpreting this data. Unlike most experiments shown in this study, trypan blue only
uses one criteria to quantify apoptosis. It relies on the premise that membrane
permeability = apoptosis. But the Annexin V staining showed that membrane
permeability does not necessarily mean apoptosis. Necrotic and mechanically damanged
cells can also lose membrane integrity. This leads to the assumption that the trypan blue
cell viability data may be slightly higher than both Wright Staining and Annexin V data.
This test is also unable to determine whether or not drug treatments are cytotoxic and
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causing cell death through necrosis, rather than apoptosis, which is an unwanted trait in a
drug treatment.

Table 3.2 - C6 Trypan Blue Data

Table 3.2: This table shows the data obtained from C6 trypan blue staining. The mean
was calculated by averaging the apoptosis percentage from trials 1-3. Standard error was
calculated with the equation: Stdev(Trials1-3)/Sqrt(3). Cell viability was calculated with
the equation: Cell viability % = 100-Mean. CI values were calculated using the
CompuSyn software. The green highlighted cell shows the lowest CI value, indicating
that QCT 25 µM + NaB 1 mM is the most synergistic drug combination in C6 GBM
cells.

Wright Stain
In situ Wright Staining of C6, T98G, and LN18 GBM cell lines painted a detailed
picture of the cell morphology differences between drug treatments on each cell line. In
C6, apoptosis was characterized by general cell shrinkage and degradation of the glial
cell protrusions. In the 25 µM QCT treatment groups, the mean apoptosis was 26.7%
with a standard error of 0.7%. The 1 mM NaB treatment groups had a mean apoptosis
amount of 24.0% with a standard error of 2.1%. The QCT + NaB treatment groups had a
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mean apoptosis of 49.2% with a standard error of 2.9%. These results showed
approximately a 95% increase in apoptosis in QCT + NaB treatment groups compared to
QCT and NaB single treatment groups. Wright Staining was also able to demonstrate
that C6 cell density became greatly reduced as drug treatments progressed. C6 is a
rapidly growing rat GBM cell line, with a tendency to form large clusters before
complete confluence is achieved. When treated with QCT + NaB, the total amount of C6
cell clusters greatly decreased. This may be due to the degradation of the extracellular
matrix proteins responsible for cell adhesion and migration such as vitronectin, laminin,
and fibronectin (Eroglu, 2009). The C6 cell clusters would un-adhere from each other
and become free-floating in the growth medium; thus, not being detected by Wright
Staining.

Figure 3.14: C6, T98G, and LN18 GBM cells visualized by in situ Wright Staining under
48-hour serum starvation. Samples were treated with either RPMI-1640, 0% FBS, 1%
P/S Control, QCT 25 µM, NaB 1 mM, QCT 25 µM + NaB 1 mM. All images were taken
under 10X magnification with an Olympus BX53 microscope.
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The T98G GBM cells had the greatest amount of apoptosis across all drug
dosages, as measured by Wright Staining. T98G control groups showed a basal level of
apoptosis averaging at 8.4% with a standard error of 1.2%. QCT single treatment groups
had a mean apoptosis of 34.4% with a standard error of 2.7%. NaB single treatment
groups had a mean apoptosis of 25.4% with a standard error of 1.2%. QCT + NaB
treatment groups had a mean apoptosis of 51% with a standard error of 2.4%. These
results showed a synergistic increase in apoptosis of 48% and 100% from QCT and NaB
groups to QCT + NaB groups, respectively. Control samples were characterized by large
cell bodies and wide astrocytic protrusions. In QCT treatment groups, apoptosis was
characterized by nuclear condensation, cell shrinkage, nuclear fragmentation, and
membrane blebbing. Both single QCT and NaB treatment groups had these cell
characterizations. However, QCT + NaB treatment groups had significant cell lysis, as
seen by the copious amounts of cell debris surrounding the cell colonies.

Figure 3.15: A graphical representation of apoptotic cells measured by Wright Staining.
This graph was generated in Microsoft Excel 2016.
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The LN18 showed a significant increase in apoptosis aswell, but was overall
characterized as the least impacted by the dual QCT + NaB drug treatments. Control
samples showed a basal level of apoptosis of 9.34% with a standard error of 1.71%. QCT
treatment groups showed an average apoptosis of 27.16% with a standard deviation of
3.16%. NaB treatment groups showed an average level of apoptosis at 22.02% with a
standard deviation of 1.73%. QCT + NaB treatment groups showed an average level of
apoptosis at 39.69% with a standard deviation of 2.01%. LN18 control samples are
characterized by an overall smaller structure than T98G. LN18 resembles epithelial cells,
while T98G resembles larger brain fibroblasts. Apoptotic LN18 was identified mainly by
nuclear condensation and cell shrinkage. QCT + NaB samples had detectable amounts of
cellular debris, which indicated cell lysis. But these amounts were significantly less than
the QCT + NaB T98G samples.

Table 3.3 - Wright Stain Data

Table 3.3: This is a numerical representation of the quantified levels of apoptosis
measured via Wright Staining. All numbers were calculated with the formula:
%Apoptosis = (#Apoptotic/Total Cells)*100. Between 200-300 cells were counted per
dose per trial.
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The main downfall of the quantification of apoptosis with Wright Staining is the
subjective nature of the test. Due to the many morphological signs of apoptosis and each
cell-type having unique characteristics, the counted number of apoptotic cells may vary
between individuals. The main purpose of Wright Staining is to visualize the
morphological changes that occur under various drug treatments. Quantifying apoptosis
relative to the control can also act in a supplementary manner to Annexin V apoptosis
quantification.

Annexin V
Annexin V/PI analysis on C6, T98G, and LN18 GBM cells yielded apoptosis vs
necrosis data based off phosphatidylserine externalization and membrane integrity. C6
GBM cells showed the lowest basal level of apoptosis at 9.1% with a standard error of
1.09%. Having C6 be the cell line with the lowest amount of Control-apoptosis was
expected due to the rapidly proliferating nature of C6. QCT-only samples showed a
mean apoptosis of 32.2% with a standard error of 3.0%. NaB-only samples showed a
mean apoptosis of 22.0% with a standard error of 0.35%. QCT 25 µM proved to be
approximately 46% more potent on C6 cells than NaB, which is reinforced by the data
obtained by Wright Staining. QCT + NaB samples showed a mean level of apoptosis of
39.5% with a standard error of 3.5%. Compared to the control sample, QCT + NaB
samples had a 77% increase in apoptosis. However, QCT compared to QCT + NaB
samples only had an 18.4% increase in apoptosis.
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Figure 3.16: Flow cytometry dot plots generated by CXP Cytometer software by
Beckman Coulter. Quadrant A1 represents FITC -/PI+ cells showing mechanical damage.
Quadrant A2 represents FITC+/PI+ cells showing late apoptosis. Quadrant A3 represents
FITC-/PI- cells showing full viability. Quadrant A4 represents FITC +/PI- cells showing
early apoptosis. Percentages shown are the averages of all trials for each sample.

T98G control samples showed a slight increase in basal apoptosis compared to
C6, at an average of 10.3% with a standard error of 0.58%. QCT-only samples showed
significant increase in apoptosis with a mean of 36.1% and a standard error of 3.6%.
NaB-only samples had a mean apoptosis of 28.7% with a standard error of 1.9%. QCT
had a greater impact on T98G cells compared to NaB by about 20.5%. QCT + NaB
samples had a mean apoptosis amount of 43.0%, which is the highest amount out of C6,
T98G, and LN18 GBM cell lines. Compared to the control samples, QCT + NaB had a
76% increase in apoptosis, which is similar to the C6 samples. But QCT compared to
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QCT + NaB samples showed only a 16% increase in apoptosis, compared to C6 samples
having an 18.4% increase in apoptosis.

Figure 3.17: Annexin V data visualization made in Microsoft Excel 2016. Data was
analyzed via one-way ANOVA followed by a Fisher post-hoc test for statistical
significance.

LN18 control samples had a mean apoptosis of 9.8% with a standard error of
1.0%. QCT-only samples had a mean apoptosis of 32.2% with a standard error of 0.94%.
These results were very similar to the C6 QCT-only levels of apoptosis of 32.2%. NaBonly samples had a mean apoptosis level of 23.6% with a standard error of 0.66%. These
measurements were also similar to the C6-NaB samples of 22%. QCT + NaB samples
had a mean apoptosis of 34.9% with a standard error of 2.0%. LN18 had the least overall
apoptosis with the QCT + NaB drug combination. But despite LN18 having the lowest
effect from the QCT + NaB combination treatment, it still had a 71% change in
apoptosis.
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Table 3.4 - Annexin V Data

Table 3.4: This shows the data table for C6, T98G, and LN18 Annexin V trials. Standard
error was calculated with the equation [Standard Error = StDev/Sqrt(3)]. Cell viability
was calculated with the equation [Viability % = 100-MeanApoptosis]. P-values were
calculated using the Minitab Express software with a one-way ANOVA followed by a
Fisher post-hoc test.
Despite Annexin V being a well accepted test for the quantification of apoptosis,
it is not without its downfalls. The greatest downfall for this test is the possibility of
mechanical damage when preparing samples. T98G is the best example for mechanical
damage possibly altering results. The human GBM cell lines T98G and LN18 are
significantly more adhesive than the rat cell line C6. The cells are also much larger, as
seen with Wright Staining. Due to the greater adhesive properties of the GBM human
cell lines, vigorous cell scraping along with longer trypsinization times were used to
harvest a satisfactory number of cells to be measured on the flow cytometer.

64

Acridine Orange
Acridine orange staining was used to visualize and quantify the total amount of acidic
vesicular organelles (AVOs) in a cell population. It has been widely proven that the
quantitiy of AVOs directly correlates to the amount of cells undergoing autophagy.
Therefore, in order to visualize autophagy progression, AO staining was performed
viewed via flow cytometry and flourescent microscopy.
Control and NaB images demonstrate how the small acidic lysosomes become
widely distributed throughout the cell; in some cases completely englufing the cell body
(as seen in T98G). Since QCT and QCT + NaB samples showed almost a complete
inhibition of autophagy, the AO-stained images are able to show the distribution of acidic
lysosomes as seen in a normally functioning cell. The autophagy inhibited cells are seen
to have several small acidic lysosomes spread throughout the cell that play a role in
routine cellular maintenance.

Figure 3.18: Acridine orange staining on C6, T98G, and LN18 cells shows acidic
vesicular organelles engulf a cell undergoing autophagy. Bright red flourescence
indicates an AVO. All images were taken at 40X magnification on a LeicaDM 2500
fluorescent microscope with a Texas Red filter.
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C6 and T98G acridine orange stained samples were run through a flow cytometer
to quantify the amount of light emission in the FL-3 channel, which directly correlates to
the amount of autophagic cells in a population. The results showed a 25-30% increase in
autophagy within 12 hours of serum starvation. C6 and T98G cells appeared to have the
greatest amount of autophagy after 24 hours of serum starvation. After 48 hours of serum
starvation, the total FL-3 density in C6 and T98G cell lines began to diminish. This
could be due to be beginning of autophagy-induced cell death, which may also account
for the 6-10% apoptosis seen in Annexin V & Wright Staining control samples.

Figure 3.19: A graphical representation of autophagy expression measured by FL-3
density on a Cytomics FC500 Flow Cytometer. All samples are normalized to a 0 hr
autophagy of 0%. All statistics were calculated on Minitab Express software.
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After 24 hours of QCT, NaB, and QCT + NaB treatment, changes in autophagy
expression began to occur. QCT-only samples showed a drastic reduction in autophagy
levels in both C6 and T98G cell lines, with the greatest reduction occurring in T98G.
NaB showed that it has very little impact on autophagy expression in both cell lines.
QCT + NaB samples showed a synergistic effect on autophagy reduction in T98G cells,
but showed slight antagonism in C6 cells. This result may explain why T98G has greater
amounts of apoptosis in QCT + NaB combinations than C6 and LN18 cell lines. Since
QCT + NaB is reducing protective autophagy, T98G cells may be more susceptible to
treatment.

Table 3.5 - Acridine Orange Stain Data

Table 3.5: Data tables showing C6 and T98G AO stain flow cytometry data. All samples
were normalized to the non-serum starved 0 hr samples. Standard error was calculated
using the equation: Stdev(Trials1-3)/Sqrt(3). P-values were calculated using a one-way
ANOVA and Fisher post-hoc test in the Minitab Express software.
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Western Blot
Western blotting was performed on C6 GBM cell lines and showed a detailed
mechanism into how QCT, NaB, and QCT + NaB promote apoptosis. All samples were
prepared using the previously outlined experimental protocol. Based off the previously
mentioned experiments, QCT is the primary inducer of apoptosis with NaB
supplementing its effects. As mentioned in Taylor and Ray, 2017, QCT acts primarily
through activation of Caspase-3, 9, and increasing the Bax:Bcl-2 ratio. In addition to
those apoptotic markers, PARP and survivin were also measured. PARP is a nuclear
protein that contributes to many cellular processes including DNA repair, cell division,
and apoptosis regulation (Zmuda et al., 2015). Survivin is a well-known apoptosis
inhibitor that is highly upregulated in many forms of cancer, including GBM (Garg et al.,
2016). A visualization of these proteins would provide a basic understanding of how
QCT and NaB interact with each other to induce apoptosis.
Bcl-2 family genes are crucial for the regulation of apoptosis. This family
consists of both pro- and anti-apoptotic genes that contribute to apoptosis through a
variety of mechanisms, namely the intrinsic apoptosis pathway (Asmarinah et al., 2014).
Bcl-2 is an anti-apoptotic protein that is located on the mitochondrial membrane and
endoplasmic reticulum (Tsujimoto, 1998). Bcl-2 prevents apoptosis by preventing the
release of cytochrome c and apoptosis inducing factor (AIF) from the mitochondrial
membrane; thereby preventing the activation of the various caspases necessary for
apoptosis induction. Many studies have shown that Bcl-2 upregulation can lead to
chemo- and radioresistance in many cancers, including GBM. This makes Bcl-2
inhibitors a promising target for cancer therapy development.
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Bax is a pro-apoptotic member of the Bcl-2 family. Within the intrinsic apoptotic
pathway, mitochondrial outer membrane permeabilization is considered the point of no
return. To arrive at this point, pro-caspase 8 is cleaved into caspase-8 which then cleaves
BID  tBID. Promotion by tBID allows Bax to attach onto the outer mitochondrial
membrane and forms pores, which then allows cytochrome C to exit the mitochondria
and continue down the intrinsic mitochondrial pathway (Raemy and Martinou, 2014).
Bax, along with Bak are directly responsible for mitochondrial permeabilization; thus, the
furthering apoptosis.
Many studies have shown that comparing a tumor’s Bax:Bcl-2 ratio can provide
insight into how susceptible a tumor may be to chemo-/radio-resistance and how easily it
may be treated (Mohammadian et al., 2016). High levels of intracellular Bax along with
low levels of intracellular Bcl-2 can make a cell more apt to react to apoptotic stimuli;
whereas the reverse can induce resistance to treatment and assist in tumor progression.
Upregulation of STAT3, a human transcription activator, is able to increase Bcl-2
expression (Mohammadian et al., 2016). However, it has been documented that QCT
downregulates JAK1 in glioblastoma, which is the upstream activator of STAT3 (Taylor
& Ray, 2017). This leads to the hypothesis that QCT has the potential to lower Bcl-2
levels in both the single QCT samples and dual QCT + NaB samples.
This study showed evidence that QCT in combination with NaB increased the
Bax:Bcl-2 ratio. This means that the intrinsic apoptotic pathway is progressing due to the
QCT + NaB treatment. In the QCT-only samples, Bcl-2 was greatly inhibited while
levels of activated Bax stayed relatively the same. NaB-only samples had a slight
increase in Bax but little inhibition of Bcl-2. It has been well documented that QCT acts
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through the intrinsic apoptosis pathway in GBM. The results obtained in this study
remain conflicting due to the relatively small changes occurring to Bax and Bcl-2 in
QCT-only doses along with the increase in both Bax and Bcl-2 levels in QCT + NaB
doses. More investigation into the mitochondrial apoptosis proteins must be done in
order to adequately draw a conclusion on whether QCT & NaB act synergistically in
altering the Bax:Bcl-2 ratio.

Figure 3.20: Western blotting of C6 cells treated in 48-hour serum starved conditions
with either 25 µM QCT, 1 mM NaB, or QCT + NaB in combination. This blot shows
both Bax (24 kD), cleaved Bax (21 kD), and Bcl-2 (26kD). Primary rabbit antibody was
diluted 1:500 and the secondary HRP-conjugated antibody was diluted 1:10,000.
Primary incubation took place overnight at 4°C and secondary incubation took place at
RT for 30 minutes.
Caspases are a family of proteases that perform essential roles in the cell cycle
and apoptosis. They act by performing a nucleophilic attack on aspartate residues on
proteins; thus, performing proteolytic cleavage on the target proteins (Gervais et al.,
1999). Caspase-3 may be one of the most widely studied caspase due to it being the
primary executioner of apoptosis. After Bax acts on the mitochondria through the
intrinsic apoptosis pathway, cytochrome C is released. Cytochrome C attaches to Apaf-1
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in the cytosol, forming the apoptosome. The apoptosome then activates pro-caspase-9,
an initiator caspase. This, in turn, activates effector caspases such as caspase-3.
Caspase-3 can be activated by either the extrinsic pathway through caspase-8 or through
the intrinsic pathway through caspase-9 (Reubold et al., 2011). Due to the crucial role of
caspase-3 in apoptosis, many studies use the measurement of caspase-3 to analyze
apoptotic cells in a population. This study is measuring both pro-caspase-3 (inactive) and
cleaved caspase-3 (active) to determine how much apoptosis is being induced by each
drug treatment.

Figure 3.21: Western blotting of C6 cells treated in 48-hour serum starved conditions
with either 25 µM QCT, 1 mM NaB, or QCT + NaB in combination. This blot shows
cleaved caspase-3 (active). Primary rabbit antibody was diluted 1:1000 and the
secondary HRP-conjugated antibody was diluted 1:10,000. Primary incubation took
place overnight at 4°C and secondary incubation took place at RT for 30 minutes.
C6 control samples show almost no cleavage of caspase-3, meaning little-to-no
apoptosis is occurring. QCT-only samples have a slight increase in apoptosis, which can
be seen by the lower amounts of pro-caspase-3 and a band appearing for cleaved caspase3. NaB-only samples do not have much activation of caspase-3, but a slight of cleaved
caspase-3 can be seen forming. The most interesting aspect is the clear synergistic
increase of cleaved caspase-3 in the QCT + NaB samples. This demonstrates that QCT
and NaB are acting in synergism to promote higher amounts of apoptosis than QCT
alone.
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PARP is a protein residing in the nucleus that is responsible for ADP-ribosylation,
which mediates a plethora of cellular processes including repair of single-stranded DNA
breaks, cell division, and apoptosis regulation (Zmuda et al., 2015). In general, PARP is
associated with continued cell survival. Because of this, PARP inhibition has been a
widely-studied avenue for cancer therapy. The goal of PARP inhibition is to allow
cancer cells to become more susceptible to DNA damaging chemotherapeutic agents,
such as temozolomide (Zhu et al., 2015). PARP is inhibited through proteolytic
cleavage, namely by the caspase proteins. It has been shown that almost all known
caspases cleave PARP in some way. Cleavage of PARP is one of the most fundamental
aspects of apoptosis (Chaitanya et al., 2010).
This study is aims to compare the activation of caspase-3 with the inactivation of
PARP. The data collected on C6 shows a normal level of PARP activation in the control,
QCT, and NaB samples. Despite the slight activation of caspase-3 by the single-dosed
drugs, neither drug by itself was able to adequately inhibit PARP in any meaningful
fashion. However, C6 cells treated with QCT + NaB showed a significant decrease in
active PARP. This is another example of how QCT and NaB are profoundly synergistic
with each other.

Figure 3.22: Western blotting of C6 cells treated in 48-hour serum starved conditions
with either 25 µM QCT, 1 mM NaB, or QCT + NaB in combination. This blot shows
active PARP-1. Primary rabbit antibody was diluted 1:1000 and the secondary HRPconjugated antibody was diluted 1:10,000. Primary incubation took place overnight at
4°C and secondary incubation took place at RT for 30 minutes.
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The impact of the QCT + NaB inhibition of PARP opens the door for many anticancer treatment avenues to be explored. Since PARP is a crucial DNA repair protein,
downregulation can potentially hinder the resistance of GBM to many DNA damaging
agents in-vivo. As previously mentioned in chapter 1, GBM becomes resistant to TMZ (a
DNA alkylating agent) within about 15 months due to O6-methylguanine DNA
methyltransferase repairing the resulting DNA damage caused by treatment (Taylor &
Ray 2017). Zhu et al. has suggested that PARP upregulation found in GBM is a major
contributor to TMZ desensitization over time. By using QCT and NaB in conjunction
with TMZ, GBM chemoresistance can be slowed; thus, allowing for a better prognosis in
GBM patients.
Survivin is a member of the inhibitor of apoptosis (IAP) protein family. This
family of proteins plays a major role in the regulation of apoptosis. The IAP family,
along with survivin, includes XIAP, cIAP1, and Livin. Many speculate that increased
survivin expression in cancer cells enables tumor progression through a variety of
mechanisms (Gang et al., 2016). High survivin expression inhibits both the intrinsic and
extrinsic apoptosis pathways by inhibiting caspase activation (Tamm et al., 1998). Direct
binding of survivin to initiator and effector caspases is still being debated; however,
survivin has been shown to bind directly to SMAC/DIABLO to prevent caspase
activation (Garg et al., 2016). In addition to the inhibition of apoptosis, survivin has also
been shown to upregulate VEGF expression in many cancer cells. VEGF is important in
tumor angiogenesis because it enables nutrients to be provided to rapidly growing tumors
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(Fernandez et al., 2014). These pro-tumor properties of survivin make it an ideal target
for cancer therapy development.
This study showed a significant synergistic decrease in survivin expression with
QCT and NaB combination. Control samples of C6 displayed a basal level of survivin
expression, which is to be expected. QCT-only samples demonstrated that QCT by itself
is a survivin inhibitor. But in all trials, QCT failed to completely inhibit all survivin
expression. NaB-only samples showed that NaB is not a survivin inhibitor when acting
alone. However, QCT + NaB in combination with each other showed almost a complete
inhibition of survivin expression. QCT is inducing NaB to develop a property that is not
typically seen when NaB is acting by itself. This demonstrates that QCT and NaB are
working synergistically with each other to inhibit survivin expression.

Figure 3.23: Western blotting of C6 cells treated in 48-hour serum starved conditions
with either 25 µM QCT, 1 mM NaB, or QCT + NaB in combination. This blot shows
active Survivin. Primary mouse antibody was diluted 1:1000 and the secondary HRPconjugated antibody was diluted 1:10,000. Primary incubation took place overnight at
4°C and secondary incubation took place at RT for 30 minutes.

Many studies have been conducted on ways to inhibit survivin expression.
Immunotherapies, small molecule inhibitors, and gene silencing are all methods being
explored in an effort to downregulate survivin. Few studies have been conducted in
GBM that explore the synergistic potential of survivin inhibition. A 2009 study
demonstrated that QCT in combination with TRAIL induced survivin inhibition in GBM
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cells at doses ranging from 100-200 µM (Siegelin et al., 2009). This study shows QCT is
able to completely deplete survivin expression with 1/4 th of the dose.
Another method for detecting levels of autophagy within a cell population is by
measuring the protein LC3. LC3 (microtubule associated protein 1 light-chain 3) is part
of the Atg (autophagy related) family of proteins, and is a crucial component for
autophagy progression (Lee and Lee, 2016). As described in chapter 1, autophagy
consists of the formation of an autophagosome that engulfs the cellular components
destined for degradation. The autophagosome then fuses with an acidic lysosome and
subsequently degrades the engulfed components; then to be reused as nutrients for the
cell (Yang and Klionsky, 2010). Under normal growing conditions, LC3 resides mostly
in the nucleus. Upon nutrient-deficient autophagy induction, LC3 becomes deacetylated
by the deacetylase enzyme SIRT1 (Huang and Liu, 2015). LC3 then exits the nucleus
and travels into the cytoplasm where LC3 becomes a required component to
autophagosome formation and progression. In the cytoplasm, LC3 is cleaved by the
protease ATG4(B) and then conjugated to Atg7, Atg3, and Atg12. This forms LC3-II,
which is the form of LC3 bound to the autophagosome membrane. The amount of LC3II directly correlates with the number of autophagosomes; thus, quantifying autophagy
for a cell population (Lee and Lee, 2016).
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Figure 3.24: Western blotting of C6 cells treated in 48-hour serum starved conditions
with either 25 µM QCT, 1 mM NaB, or QCT + NaB in combination. This blot shows
LC3B-I (16 kD) and LC3B-II (14 kD). Primary rabbit antibody was diluted 1:1000 and
the secondary HRP-conjugated antibody was diluted 1:10,000. Primary incubation took
place overnight at 4°C and secondary incubation took place at RT for 30 minutes.

The shown results for C6 demonstrate that a significant amount of autophagy is
occurring in the 48 hr serum-starved control samples, which is to be expected. QCT-only
samples show a drastically decreased amount of autophagy, while NaB-only samples
showed similar levels of autophagy compared to the control. This indicates that QCT is
acting as an autophagy inhibitor while NaB has no impact on autophagy. QCT + NaB
samples show a decreased amount of autophagy compared to the control but an increased
amount compared to QCT-only samples. This indicates that NaB may be slightly
hindering QCT’s autophagy inhibition properties; however, the mechanism for this is
unknown. The western blot data directly correlates with the AO stain data obtained via
flow cytometry, which strengthens this conclusion.

76

Figure 3.25: C6 GBM cell western blotting. All experiments were performed according
to the previously described experimental protocol.

3.4 - FUTURE DIRECTIONS
Nanocarrier Delivery
The synergistic data gathered on QCT + NaB combination therapy in
glioblastoma points to the idea that quercetin has the potential to be a viable second-line
glioblastoma therapy when combined with complementary drugs. But unfortunately,
QCT has some downfalls that must be addressed before it can successfully be furthered
into in-vivo studies. Quercetin is an abundant bioflavonoid that can be found in many
common foods. But because QCT originates from food, the body has become very
efficient at inducing its breakdown, making it largely incapable of being stored in tissues.
For QCT to be used as an anti-cancer therapy, a delivery mechanism must be developed
that enables QCT to evade metabolism and penetrate the blood brain barrier.
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Most studies conducted about QCT brain delivery focus on the anti-oxidant
property of QCT. However, much of this data can also be applied to QCT as an anticancer agent. A study conducted on intravenous administration of QCT-loaded
nanosomes on newborn piglets demonstrated that QCT was delivered to the brain with a
concentration of 3.64 nM 60 minutes after administration (Blasina et al., 2015).
Although this concentration allows QCT to act as a neuroprotectant, its final
concentration is not conducive for anti-cancer activity. Another study investigated the
potential of QCT brain delivery using QCT-loaded nano lipidic carriers. They measured
a QCT concentration in brain tissues of 68.3 nM 12 hours after administration (Kumar et
al., 2016). But this concentration is still significantly lower than any µM concentration
where QCT could exert anti-cancer properties. Recently, however, a study was
performed using freeze-dried polymeric micelles to encapsulate quercetin to be used as
an in-vivo glioma treatment in rats. They demonstrated that gastric administration of
QCT-loaded micelles significantly increased the survival time and decreased tumor
volume in glioma-infected rats. Median life expectancy was increased by 2-fold in
treated rats compared to control specimens (Wang et al., 2016). These studies have
shown that quercetin metabolism in the liver and exclusion by the blood brain barrier can
be avoided with the use of lipid-based nanocarriers. In the future, more investigation
must occur in the anti-cancer capabilities of QCT in-vivo.
PARP Inhibition with Temozolomide
One of the greatest hurdles medicine faces when treating GBM is the rapid
chemoresistance that develops when undergoing temozolomide treatment. TMZ acts as a
DNA alkylating agent that transfers a methyl group to DNA by forming an unstable
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methyldiazonium cation at physiological pH. The addition of a methyl group at the O 6
guanine position is the source of TMZ cytotoxicity and results in glioblastoma cell death
(Messaoudi et al., 2015). Unfortunately, in about 15 months, many GBM patients
become resistant to TMZ. This mostly occurs through the MGMT DNA repair enzyme.
MGMT removes methyl groups from DNA by permanently attaching itself to the methyl
group, prompting inactivation and degradation by a proteasome (Messaoudi et al., 2015).
In order to combat TMZ resistance in GBM, drug synergism remains one of the most
promising options. Many clinical trials are underway with hopes of combating MGMTinduced GBM chemoresistance, however most have had little success. A 2014 trial
investigated the benefit of combining Cilengitide with standard TMZ treatment in
glioblastoma patients and found minimal benefit to overall survival (Stupp et al., 2014).
Many more clinical trials have been conducted aiming to combat TMZ resistance with
few promising results (Messaoudi et al., 2015).
Another available strategy for inhibiting GBM TMZ resistance is PARP
inhibition. PARP is a protein that plays a crucial role in the DNA base excision repair
(BER) system, which is activated by DNA damage caused by agents such as TMZ
(Messaoudi et al., 2015). Many studies have suggested that introducing a PARP inhibitor
to routine GBM treatment may re-sensitize tumors to treatment. For example, a 2017
study studied the impact that Veliparib, a potent PARP inhibitor, had on GBM cell lines
taken from patients who had already undergone standard GBM treatment and had
subsequently become resistant. Their in-vivo results obtained from nude mice showed
that a PARP inhibitor combined with radiation therapy improved survival times by 1222% (Jue et al., 2017).
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Our results showed that QCT in combination with NaB acted as a potent PARP
inhibitor in serum-starved C6 rat glioma cells. A potential avenue to be explored could
be with PARP combination treatment as a precursor to TMZ. This could promote
downregulation of survivin and PARP to allow enhanced TMZ sensitivity.

3.5 - CONCLUSION
This study investigated the synergistic efficacy of quercetin and sodium butyrate
in glioblastoma. The results showed morphological signs of apoptosis that included
membrane blebbing, cell shrinkage, and chromatin condensation. Additional apoptosis
quantification with Annexin V/PI staining showed a marked increase in apoptosis with
QCT + NaB combination compared to single-dosed drugs in C6, T98G, and LN18
glioblastoma cell lines. The highest amount of apoptosis was found in the T98G
glioblastoma cell line at approximately 43%. Similar amounts of apoptosis are typically
seen in GBM cells treated with a single dose of QCT at 100 µM (Kim et al., 2013).
These results support the idea that QCT in combination with synergistic compounds, such
as NaB, produce similar anti-cancer effects at drastically lower concentrations. This
approach has the potential to overcome the ongoing issue of delivering QCT to brain
tissues at high enough concentrations to enable its anti-cancer effects as opposed to its
anti-inflammatory neuroprotective effects. By lowering the QCT anti-cancer
concentration threshold, lipid-based nanocarriers may soon be developed to enable
quercetin to be a viable glioblastoma treatment.
Acridine orange staining by fluorescence microscopy and flow cytometry was
used to measure and quantify autophagy in serum-starved GBM cells. Flow cytometry
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results showed that QCT was a powerful autophagy inhibitor in all GBM cell lines, but
showed the greatest impact in the T98G cell population. QCT and QCT + NaB samples
showed a complete reversal of autophagy in T98G cells. The findings in T98G contradict
the findings of Badziul et al. saying that QCT alone is a weak autophagy inducer in T98G
cells. Western blot analysis of LC3B in C6 cells showed QCT-induced autophagy
inhibition with slight antagonism in QCT + NaB samples. This data was confirmed with
AO staining. QCT as an autophagy inhibitor opens the door for enhanced glioblastoma
treatment by reducing protective autophagy.
Western blotting in C6 showed synergism in caspase-3 activation, survivin
inhibition, and PARP inhibition. Caspase-3, being one of the hallmarks of apoptosis,
further demonstrates the synergistic effects of QCT and NaB on apoptosis induction.
Survivin inhibition was obtained at drastically lower than previously seen concentrations
in other quercetin combination studies (Siegelin et al., 2009). PARP inhibition caused by
synergistic interactions between QCT and NaB shows the potential for this therapy to
sensitize TMZ resistant cells for further treatments.
Overall, quercetin has been shown to be a powerful anti-cancer agent in glioblastoma.
Despite the hurdles faced with quercetin-based treatment development, promising
avenues have emerged. Quercetin pairing with synergistic compounds, such as sodium
butyrate, enables effective quercetin concentrations to be drastically lowered. Continued
synergistic studies, along with the development of efficient nano-delivery systems, could
make quercetin administration a viable treatment for glioblastoma patients and give them
a better chance at defeating this devastating disease.
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